“We’re creating a whole new model of research, working side by side with leading academics on a number of exciting programs, ranging from kidney disease to Alzheimer’s. My team is collaborating on TM4SF1, a protein indicated in prostate cancer, with a true giant in the field, Dr. Hal Dvorak of Beth Israel Deaconess Medical Center. We’re pushing the science forward and learning so much from each other, so quickly, it’s inspiring.”

OWNING COLLABORATION

Alberto Visintin
Associate Research Fellow

Working Together to Speed the Science

Pfizer’s Centers for Therapeutic Innovation (CTI) represents a significant departure from the traditional lengthy and linear process of target discovery to eventual drug development. Collaborations such as the one between CTI Boston and Dr. Hal Dvorak of Beth Israel Deaconess Medical Center exemplify this new model, which seeks to expedite the translation of science into medicine.

CTI’s open innovation model puts Pfizer scientists side by side with academic investigators in the lab, where they share their understanding of target biology and translational medicine expertise. Pfizer funds preclinical and clinical development programs and offers equitable intellectual property and ownership rights to our CTI partners. In addition, we provide access to select Pfizer compound libraries, proprietary screening methods, antibody development technologies, and a wealth of dedicated resources and support from Pfizer experts in drug development and protein sciences.

The ultimate goal of each collaboration is to validate a drug candidate that can be moved into further clinical testing.
“An academic lab can only go so far. We’re good at identifying targets, but if you want to make monoclonal antibodies or take this to the clinic…a partner like Pfizer offers extraordinary resources.”

DR. HAL DVORAK
Beth Israel Deaconess Medical Center

Dr. Dvorak, a research pioneer whose ideas helped spur the advance of targeted cancer drugs, was one of the first scientists to demonstrate that cancer cells secreted vascular endothelial growth factor, the initial idea behind the development of drugs that cut off the blood supply to tumors to stop their spread.

Delivering on the Promise

With four locations in the biomedical research hubs of Boston, New York, San Diego and San Francisco, and a network of 20 academic medical center partners, CTI now has a portfolio of 26 programs across a variety of disease areas. Leveraging the respective strengths of these efforts, Pfizer hopes to demonstrate “proof-of-mechanism” on three candidate selections per year beginning in 2013.

26 CTI PROGRAMS
In Development

20 ACADEMIC MEDICAL CENTERS
Partnering with CTI

TM4SF1 Program

The TM4SF1 protein is over-expressed in tumor-feeding vasculature and certain cancers (such as colon and liver), presenting a potential target for monoclonal antibodies designed to destroy tumor-feeding vessels, thus starving cancer from its nutrients and inducing its regression. This program began with an antibody asset identified by Dr. Dvorak and his proposal for developing an antibody conjugate therapy. In the collaborative process with CTI, the team developed an antibody drug conjugate that is being tested for safety and efficacy in animal tumor models. The collaboration eventually included Global Biotherapeutics, CTI La Jolla and Pfizer’s Oncology research unit. In a little over a year, a lead biologic candidate was exhibiting great efficacy in not only reducing tumors in vivo but also in keeping the tumors from growing back. Development continues. It is estimated that this particular collaboration has taken several years and great expense out of the development process.
“We worked on Xeljanz for 20 years, from discovery through registration. As a medicinal chemist on the program, I devoted over three years to synthesizing and profiling a thousand analogs. To see the promise delivered, and actual patients getting real-life benefits from our work…it’s humbling. And it feels very, very good. I consider myself incredibly lucky to have played a part.”

Mark Flanagan
Associate Research Fellow

A Novel Treatment Emerges

Xeljanz is the first new oral disease-modifying antirheumatic drug approved for rheumatoid arthritis in more than ten years and the first rheumatoid arthritis treatment in a new class of medicines known as Janus kinase (JAK) inhibitors. Unlike biologic therapies, which work outside the cell, Xeljanz targets the inflammation associated with rheumatoid arthritis from inside the cell. Specifically, Xeljanz inhibits the JAK pathways, which are signaling pathways inside cells that are used by pro-inflammatory cytokines (proteins that facilitate communication between cells).

Approved in the U.S. for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, Xeljanz is currently under review by several regulatory agencies around the world.
A Product of Pfizer Science

Discovered by Pfizer scientists in our Groton, Connecticut, laboratories, Xeljanz was developed solely by Pfizer.

20 YEARS
From Discovery to Approval

400,000
Compounds Screened

1,000
Compounds Synthesized

Rheumatoid Arthritis

Rheumatoid arthritis is a debilitating disease of the joints characterized by a cycle of inflammation involving different pro-inflammatory cells and processes inside the body.

Rheumatoid Arthritis Affects

23.7 MILLION
People Worldwide

1.6 MILLION
People in the U.S.
“Patient safety is a core value and our absolute first priority—from the moment a compound is cleared for clinical trials, to its approval by regulators for use by patients, through its manufacture and distribution, and for as long as it is for sale and in use anywhere in the world.”

OWNING
TRUST

Freda Lewis-Hall, M.D.
Chief Medical Officer

Empowering Physicians and Patients

We work tirelessly to help doctors and patients use our medicines and vaccines safely, effectively and appropriately.

Physicians and other health care professionals empowered to write prescriptions are the key “gatekeepers” of our products. A prescription for a Pfizer medicine means that the patient and the health care professional have made a careful decision on a course of treatment. Around the globe and around the clock, we provide call services so that questions from doctors and other prescribers can be answered in a timely way by our well-trained medical staff. We also provide online and mobile resources, and are working on point-of-care smart phone apps, for even faster response. For patients and caregivers, we offer a variety of websites to help maintain and improve health, and to assist in the safe, effective and appropriate use of our products. Our Medicine Safety Education website, for example, shows how a medicine’s safety profile is determined, monitored and communicated, and even includes a direct link to MedWatch, the U.S. FDA’s Safety Information and Adverse Event reporting program.

We provide such information so that prescribers and patients alike can make the best health care decisions and have the opportunity for the best health care outcomes. Keeping people informed will become even more important in the years to come, as medicines become more precise and are developed to meet the needs of very specific subgroups of patients. We are committed to continued leadership in keeping prescribers and patients fully informed about our medicines.
Ensuring Data Integrity

People must trust the systems that enable regulators to evaluate the safety of new medicines and vaccines. We conduct hundreds of audits a year to affirm the integrity of the data we provide to regulators, with a special focus on making sure our clinical trials are executed properly.
“I spent four months in Uganda working to improve maternal, newborn and child health as a Pfizer Global Health Fellow with Save The Children. It was an amazing experience. We were in the heart of Kampala, the capital city, working on building coalitions among national, regional and global stakeholders. I learned so much, particularly about what collaboration can do, especially when resources are limited, and how diversity and different experiences bring strength and innovation to a team.”

For the past decade, Global Health Fellows like Jeffrey have worked hand-in-hand with international development organizations to strengthen health care infrastructure, capacity and awareness in under-resourced communities. Sharing best practices and private-sector knowledge, they learn how to leverage existing resources to create tangible and sustainable improvements in public and private health care delivery. Fellowship focus areas align with Pfizer expertise, such as supply chain management, health prevention programming and business development.

The program promotes access, quality and efficiency of health care delivery for people in greatest need around the world. In return, Fellows and Pfizer gain new perspectives on global health challenges and how the public and private sectors can work together to address them.
Pfizer’s Global Health Fellows Program

Global Health Fellows is our signature international corporate volunteer program that places Pfizer colleagues and teams in short-term assignments with leading international development organizations in under-resourced communities around the world. For more on the program, including profiles of current and past Fellows, go here.

The program is part of Pfizer’s Investments in Health platform that focuses on leveraging the full range of our resources — people, medicines, expertise and funding — to broaden access to medicines and strengthen health care delivery for underserved people around the world. For more information on our social investments, go here.

40 PARTNERSHIPS
With international development organizations over the life of the Global Health Fellows program.

95%
Of Fellows strongly agree that their fellowships expanded understanding of global health challenges and patient population needs.

317 COLLEAGUES
Have served as Pfizer Global Health Fellows since 2003.

40+ COUNTRIES
Including the U.S., since 2003

317 COLLEAGUES

94%
Of Fellows agree on the importance of this program to developing professional skills.

40+ COUNTRIES

89%
Of Fellows agree that participation in the program sparked new ideas for products, services and improvements that they can apply to their work at Pfizer.
“What I love about Get Old, it’s getting people to discuss healthy aging and share their experiences. This empowers people in their health care. As a physician, as a geriatric psychiatrist, as a human being, I’ve always had a passion for community outreach. In person. I was reluctant to entertain the idea of social media. But Get Old got me so excited, I got a Twitter account so I could participate!”

Get Old is a community created to encourage and support a dialogue about getting older and living better, where people of all ages can explore helpful health and aging information, along with stories from across our community. We invite everyone to tell their stories, and contribute their thoughts and experiences on growing up and growing old.

What Is Get Old?
It’s about...
- Not just living longer, but having a better quality of life at any age
- Celebrating the experiences, wisdom and knowledge that come with getting older
- Providing useful, actionable information that can help people take control of their health at every stage of life
- Connecting with people around a common truth—that everyone wants to live the longest, fullest life possible
- Taking on an important issue affecting society, the health care system and government—our aging population
Annu Al Review 2012

When you have more time, you get to see more. You get to do more. You get to share more. You get to make more wrong turns and explore places you might never have gone to. You get to experience more successes. And just as important, more failures. It’s a chance to not just live longer, but to live fuller.

Ultimately, your job is to get to work on your dreams. Ours is to make sure you live long and well enough to achieve them.

Age-Friendly Cities

The Pfizer Foundation and Grantmakers in Aging have awarded $1.3 million to support Community AGEnda, a partnership with five American communities to accelerate their efforts to become great places to grow up and grow old. Building on the World Health Organization’s Age Friendly Cities initiative, this one-year pilot program focuses on age-friendly community development in Phoenix, Atlanta, Miami, Greater Kansas City and the State of Indiana. This initiative will help advance the efforts of all cities working to create better communities for older adults and people of all ages.

Get Old

Top Fears About Getting Old

When you have more time, you get to see more. You get to do more. You get to share more. You get to make more wrong turns and explore places you might never have gone to. You get to experience more successes. And just as important, more failures. It’s a chance to not just live longer, but to live fuller.

Ultimately, your job is to get to work on your dreams. Ours is to make sure you live long and well enough to achieve them.

28%

Of people aged 35–49 have lied about their age.

10,000 BABY BOOMERS

In the U.S. turn 65 every 24 hours.

1 OUT OF 5 AMERICANS

Will be 65 or older by 2050, according to U.S. Census projections.

2 BILLION

People worldwide will be over the age of 60 by 2050.

Top Fears About Getting Old

Dying comes in fifth on the list of things that scare people about getting old:

- 25% Living with pain and physical limitations
- 19% Becoming dependent
- 15% Being alone
- 14% Running out of money
- 10% Dying
- 9% Getting sick
- 7% Nothing

“Preventive Care and Healthy Ageing: A Global Perspective Report”

This Pfizer-sponsored report, developed by the Economist Intelligence Unit (EIU), profiles eight countries: Brazil, China, India, Japan, Russia, South Africa, the U.K. and the U.S. Its key finding: the world’s governments can help reduce rising health costs by investing in health for all age groups and in preventive care programs.
TO OUR STAKEHOLDERS:
2012 was an outstanding year for the patients we serve and for our shareholders.

2012: A MILESTONE YEAR

We brought five new therapies to patients for treating kidney cancer, leukemia, rheumatoid arthritis, stroke prevention in atrial fibrillation and the rare Gaucher disease. We drove solid revenue growth in many of our key, patent-protected products and achieved double-digit revenue growth in emerging markets. Despite an industry record $7.4 billion operational loss in sales due to patent expirations, we maintained relatively flat adjusted earnings per share* and returned nearly $15 billion to shareholders through dividends and share repurchases.

At the core of our performance in 2012 were the actions we took resulting from the four imperatives that we put in place at the beginning of 2011. Through the focus they provided, we advanced our R&D turnaround, operated efficiently to create a more-flexible cost base, met our financial commitments, and maintained high standards of quality, compliance and business ethics. Additionally, we made continued progress in our ongoing efforts to earn society’s respect and to create an ownership culture within Pfizer. I believe our culture can become a key sustainable advantage as we work to make Pfizer the premier, innovative biopharmaceutical company. That’s why we are investing time and resources to develop one unified culture that we call OWN IT!

A brief summary follows of our 2012 accomplishments for each imperative.

* See the Company’s Annual Report on Form 10-K, as amended, for the year ended December 31, 2012 for the definition of “adjusted income” and for reconciliations of 2012 “adjusted income” and “adjusted diluted earnings per share” to 2012 net income attributable to Pfizer Inc. and diluted earnings per share attributable to Pfizer Inc. common shareholders, respectively. “Adjusted diluted earnings per share,” “adjusted cost of sales,” “adjusted selling, informational and administrative expenses” and “adjusted research and development expenses” are income statement line items prepared on the same basis as, and are components of, the “adjusted income” measure.
Improving the Performance of our Innovative Core

2012 was a pivotal year for pipeline developments, with five new therapies now available that have significant efficacy and safety as well as value for patients, physicians and payers.

- **Bosulif** was approved in the U.S. for previously treated chronic myelogenous leukemia, a slowly progressing blood and bone marrow disease, which usually occurs during or after middle age. With this approval, we continue to bring to patients targeted therapies that more precisely treat their illness.
- **Eleyso** was approved in the U.S. as an enzyme-replacement therapy for Type 1 Gaucher Disease in adults, a genetic disease characterized by anemia, low platelet counts, bone disease and an enlarged liver and spleen. This development program affirms our commitment to patients suffering from rare diseases.
- **Eliquis** was approved in the U.S., Canada, the European Union and Japan as an anticoagulant. Co-developed and now co-promoted with Bristol-Myers Squibb, Eliquis has the potential to set a new standard of care in the high need area of stroke prevention for patients with nonvalvular atrial fibrillation.
- **Inlyta** was approved in the U.S., Japan and the European Union for advanced kidney cancer. This is another example of our expanding Oncology portfolio.
- **Xeljanz** was approved in the U.S. as the first new oral DMARD (Disease Modifying Anti-Rheumatic Drug) in over a decade. Xeljanz offers a totally new mechanism of action to treat rheumatoid arthritis and has a compelling clinical profile.

During 2012 we also advanced our early and mid-stage pipeline, most notably in the oncology and vaccines areas. We moved forward in phase III studies with dacomitinib for non-small cell lung cancer, inotuzumab for aggressive non-hodgkin’s lymphoma and Xeljanz for psoriasis. We initiated phase III studies for Xeljanz for ulcerative colitis, for inotuzumab for acute lymphoblastic leukemia and for a Meningococcal B vaccine for individuals aged 11-25.

These accomplishments are a result of actions we set in motion early in 2011 to improve R&D productivity. First, Pfizer scientists are now focused on the therapeutic areas where we have distinct advantages such as Neuroscience and Pain, Cardiovascular/Metabolic, Oncology, Inflammation and Immunology, and Vaccines. The chief scientist of each therapeutic area is accountable for managing resources and delivering specific results. Second, while our Groton R&D facility continues to provide important drug discovery and development expertise, many of our scientists are now located in cities considered to be hubs of biomedical innovation, such as Boston, San Francisco and San Diego. By working alongside their counterparts in academia and with biotech partners, Pfizer scientists are able to drive discovery efforts and expand our access to important enabling science and technology. Third, we are using specific metrics to assess our success rate at every stage of the development cycle to help ensure we are allocating our capital to the programs that have the highest potential for delivering value.

Through all of these actions, we are becoming increasingly rigorous in our choices of potential new medicines to move into the later, most expensive stages of development and much more agile in advancing our pipeline forward. Our latest pipeline report can be found on our [website](http://www.pfizer.com/annual).

Making the Right Capital Allocation Decisions

During 2012 we made decisions and took actions that enabled us to allocate our capital in ways that enhanced shareholder value.

We continued our multi-year, companywide program to reduce expenses. In 2012, we reduced our total adjusted Cost of Sales, Selling, Informational & Administrative expenses and R&D expenses* on an operational basis by approximately 10%, which is nearly a $4 billion reduction compared to 2011 levels.

We realized significant value for our shareholders through the sale of our Nutrition business to Nestlé for $11.85 billion, and we started to unlock value from our Animal Health business, now called Zoetis. In early 2013, we completed an IPO in which we sold approximately 20% of Zoetis to the public and a related debt offering, generating approximately $6 billion in proceeds to Pfizer.
which we plan to deploy in the best interests of our shareholders. Zoetis begins its existence as the largest stand-alone company fully devoted to animal health medicines and vaccines.

During 2012, we continued to pursue “bolt-on” business development opportunities to supplement our research efforts and product offerings. These are acquisitions or collaborative arrangements that we can readily integrate and that expand our reach or capabilities. We acquired NextWave, a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit/hyperactivity disorder. Together with Zhejiang Hisun Pharmaceuticals, we launched Hisun Pfizer Pharmaceuticals Company Limited, a joint venture to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets. We entered into an exclusive long-term collaboration with Mylan to develop, manufacture, distribute and market generic drugs in Japan. To capitalize on the strengths of our Consumer Healthcare business, we signed an agreement with AstraZeneca to obtain the over-the-counter rights to Nexium, their well-known gastrointestinal treatment. We also acquired Alacer, a company whose product, Emergen-C, fits well into our vitamins and supplements portfolio.

Earning Greater Respect from Society – A New Approach to Social Dialogue

Physicians, pharmacists, payers and governments determine how our medicines and vaccines reach patients. Being respected by these audiences and by society at large is at the core of our ability to operate.

We know that the integrity of the information and data that we provide is essential to how we are viewed and the respect and trust that society places on what we do. Our highest priority is to provide useful, transparent and credible health information and medical data. Visitors to our website can view regularly updated reports on our clinical trials and their results, as well as the post-marketing commitments we’ve made to the FDA and regulatory authorities in other jurisdictions.

Additionally, we remain committed to providing access to our medicines through a series of patient access programs, such as Pfizer Helpful Answers—a U.S. initiative that provides our medicines for free or at a savings to uninsured and underinsured patients who qualify. During 2012, this program helped 1 million patients receive more than 7 million Pfizer prescriptions.

Finally, we know we will earn greater respect by listening to people from all walks of life and providing them with information that will help them live longer, healthier and happier lives. Towards this end, in 2012, we launched a multi-year initiative, called GetOld, to forge a richer dialogue on the issue of aging—one of society’s most pressing issues affecting health care and quality of life. Since the launch of GetOld in mid-2012, we went from zero share of voice of the aging conversation online to more than a 5% share in just six months. In addition, the new external platform we launched in 2011 with our Chief Medical Officer, Dr. Freda Lewis-Hall, to connect with consumers through broadcast media reached 30 million people.

A Culture of Ownership

We are committed to creating an ownership culture that unleashes the creativity of our colleagues around the world.
In 2012, we focused on building a culture, whereby colleagues apply their expertise to take appropriate risks to innovate, are accountable for their decisions, work collaboratively, deliver on their commitments, engage in constructive debate to help ensure each other’s success, and operate with integrity and in compliance with applicable legal requirements and company policies.

Through new tools and companywide training, we are equipping leaders across the business to have open and candid conversations with colleagues and to encourage their active involvement in solving problems.

We are seeing early signs of an ownership culture taking hold as colleagues become more entrepreneurial and seize opportunities to make a difference in the business. For example, the initiative and accountability of our colleagues contributed to an earlier-than-expected approval for Xeljanz in the U.S. Likewise, during 2012 the innovative approach of the teams managing the Lipitor loss of exclusivity (LOE) resulted in a substantially greater market share compared to previous LOE analogue products in the industry.

I firmly believe having an ownership culture is what will give us the ultimate competitive advantage and it is a key priority for me and Pfizer’s entire senior leadership team.

Focused on Creating Sustained Shareholder Value

Pfizer is on the right path. As we turn to 2013, we must maintain our momentum by continuing to demonstrate fiscal discipline in how we use our capital, by delivering on the potential within our pipeline, and by executing our business plans while maintaining the highest standards of compliance and ethics.

To help us achieve maximum performance over the next several years, we will continue to use distinct operating models within developed markets and emerging markets.

In the developed markets, we have one operating model that supports our innovative-driven businesses that largely market patent-protected medicines and a second model that supports our value-driven business that largely markets medicines that are no longer patent protected.

Within emerging markets, our operating model has a geographic focus that supports both the innovative-driven and value-driven businesses. This is working well in these high-growth geographies; however, as these markets evolve, we will evaluate if the emerging markets model should more closely mirror the two distinct approaches we take for developed markets.

I would also note that we continue to enhance the value of our Consumer Healthcare business with a portfolio that includes some of the world’s best known consumer brands such as Advil, Centrum, and Caltrate. It has strong connections with emerging markets and pharmacy customers worldwide, and it gives us a platform to pursue the potential growth opportunities we see through the switches of prescription medicines to over-the-counter medicines.

Speaking for all of us at Pfizer, including our Board of Directors, I thank you for your continued confidence in our leadership. We remain firmly committed to fulfilling our company’s purpose of innovating to bring therapies to patients that significantly improve their lives. By doing that well, we will create value for the patients we serve and for our shareholders.

Sincerely,

Ian C. Read
Chairman and CEO
CEO LETTER

PERFORMANCE

Financial Performance

Three-Year Summary
as of and for the year ended December 31

<table>
<thead>
<tr>
<th>MILLIONS (Except Per Common Share Data)</th>
<th>2012</th>
<th>2011(a)</th>
<th>2010</th>
<th>12/11</th>
<th>11/10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td>$55,986</td>
<td>$65,259</td>
<td>$65,165</td>
<td>(10)</td>
<td>-</td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>$7,870</td>
<td>$9,074</td>
<td>$9,483</td>
<td>(13)</td>
<td>(4)</td>
</tr>
<tr>
<td>Restructuring charges and certain acquisition-related costs</td>
<td>$1,880</td>
<td>$2,930</td>
<td>$3,145</td>
<td>(36)</td>
<td>(7)</td>
</tr>
<tr>
<td>Income from continuing operations</td>
<td>$9,518</td>
<td>$8,395</td>
<td>$8,318</td>
<td>13</td>
<td>1</td>
</tr>
<tr>
<td>Discontinued operations—net of tax(b)</td>
<td>$5,080</td>
<td>$1,654</td>
<td>$(30)</td>
<td>207</td>
<td>*</td>
</tr>
<tr>
<td>Net income attributable to Pfizer Inc.</td>
<td>$14,570</td>
<td>$10,009</td>
<td>$8,257</td>
<td>46</td>
<td>21</td>
</tr>
<tr>
<td>Diluted earnings per common share attributable to Pfizer Inc. shareholders</td>
<td>$1.94</td>
<td>$1.27</td>
<td>$1.02</td>
<td>53</td>
<td>25</td>
</tr>
<tr>
<td>Weighted-average shares—diluted</td>
<td>7,508</td>
<td>7,870</td>
<td>8,074</td>
<td>(5)</td>
<td>(3)</td>
</tr>
<tr>
<td>Number of common shares outstanding</td>
<td>7,276</td>
<td>7,575</td>
<td>8,012</td>
<td>(4)</td>
<td>(5)</td>
</tr>
<tr>
<td>Working capital</td>
<td>$32,796</td>
<td>$31,908</td>
<td>$35,764</td>
<td>3</td>
<td>(11)</td>
</tr>
<tr>
<td>Goodwill &amp; other identifiable intangible assets, net</td>
<td>$90,685</td>
<td>$95,753</td>
<td>$98,335</td>
<td>(5)</td>
<td>(3)</td>
</tr>
<tr>
<td>Total assets</td>
<td>$185,798</td>
<td>$188,002</td>
<td>$195,014</td>
<td>(1)</td>
<td>(4)</td>
</tr>
<tr>
<td>Total debt(c)</td>
<td>$37,460</td>
<td>$38,942</td>
<td>$44,007</td>
<td>(4)</td>
<td>(12)</td>
</tr>
<tr>
<td>Total Pfizer Inc. shareholders’ equity</td>
<td>$81,260</td>
<td>$82,190</td>
<td>$87,813</td>
<td>(1)</td>
<td>(6)</td>
</tr>
<tr>
<td>Shareholders’ equity per common share</td>
<td>$11.17</td>
<td>$10.85</td>
<td>$10.96</td>
<td>3</td>
<td>(1)</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td>$17,054</td>
<td>$20,240</td>
<td>$11,454</td>
<td>(16)</td>
<td>77</td>
</tr>
<tr>
<td>Property, plant and equipment additions</td>
<td>$1,327</td>
<td>$1,660</td>
<td>$1,513</td>
<td>(20)</td>
<td>10</td>
</tr>
<tr>
<td>Purchases of common stock</td>
<td>$8,228</td>
<td>$9,000</td>
<td>$1,000</td>
<td>(9)</td>
<td>*</td>
</tr>
<tr>
<td>Cash dividends paid</td>
<td>$6,534</td>
<td>$6,234</td>
<td>$6,068</td>
<td>5</td>
<td>2</td>
</tr>
</tbody>
</table>

(a) For 2011, includes King Pharmaceuticals Inc. commencing on the acquisition date of January 31, 2011.

(b) The sale of our Nutrition business closed on November 30, 2012. 2012, 2011 and 2010 reflect the Nutrition business, which was acquired in 2009, as a discontinued operation. All financial information before 2012 reflects Capsugel (the sale of which closed on August 1, 2011), as a discontinued operation.

(c) Our short-term borrowings are rated P-1 by Moody’s Investors Service (Moody’s) and A1+ by Standard & Poor’s (S&P). Our long-term debt is rated A1 by Moody’s and AA by S&P. Moody’s and S&P are major corporate debt rating organizations.

*Calculation not meaningful.

Detailed information on our financial and operational performance can be found in the 2012 Financial Report.
Key Performance Indicators

ACCESS TO MEDICINES

11
Number of global programs and commercial transactions to increase access to medicines in emerging markets

17
Number of top 20 global burdens of disease addressed by products and pipeline

56
Number of emerging markets in which Pfizer has implemented intra-country tiered pricing

EMPLOYEES

0.59 INJURIES PER 100 EMPLOYEES

TOTAL INJURY RATE
Pfizer’s injury rate has been reduced by 52% since 2007. The rate was unchanged from 2011.

ENVIRONMENT

2.4 MILLION METRIC TONS CO₂ e6
GREENHOUSE GAS EMISSIONS
Total GHG emissions in 2012 were 4.8% lower than in 2011.

50.7 MILLION CUBIC METERS
WATER WITHDRAWAL
Total water withdrawal in 2012 was essentially unchanged, increasing by less than 1% from 2011.

186 THOUSAND METRIC TONS7
WASTE GENERATED
Total waste generated in 2012 was 4.7% lower than in 2011.

---

1. Program/commercial transaction defined as a Pfizer investment or dedicated contract of over $250,000 with a national government or procurement agency, MLO, NGO, private institution or aid agency. Represents multi-country initiatives only and does not include numerous local initiatives to address access.

2. As defined by the World Health Organization. Burdens of illness not addressed include road traffic accidents, prematurity and low birth weight, and self-inflicted injuries.

3. Represents minimum number of emerging markets with pricing tailored to different patient segments (for at least one product), allowing access for more patients.

4. Represents >90% of Pfizer employees and directly-supervised contractors.

5. Data are baseline adjusted, reported absolute, using reporting boundaries per the WRI GHG Protocol. Includes Zoetis sites (formerly Pfizer Animal Health). Excludes divested Pfizer Nutrition sites. The 2011 U.S. and Puerto Rico GHG data (60% of the footprint) was independently verified to the “Reasonable Assurance” level. Expanded environmental reporting will be posted on www.pfizer.com later this year.

6. Carbon footprint includes total direct (including fleet and aviation) and indirect emissions. Does not include Scope 3 emissions.

7. Pfizer is revising its approach to reporting spent process solvents for reclaim on-site (to be re-used in manufacturing) where they are not regulated as waste by local law. They are not now reported as waste. Based on corrected data, the overall recycling rate was 32%, and the quantity of hazardous and non-hazardous waste decreased 5% and 3% respectively from 2011.
Performance and Guidance

REPORTED REVENUES (in Billions)

ADJUSTED COST OF SALES as % of REVENUES

ADJUSTED SI&A EXPENSES (in Billions)
ADJUSTED R&D EXPENSES\(^5\) (in Billions)

\[\begin{array}{cc}
6.0 & 6.2 \\
6.4 & 6.5 \\
6.8 & 7.0 \\
7.2 & 7.4 \\
7.6 & 7.8 \\
8.0 & \\
\end{array}\]

- **2013 GUIDANCE\(^4\)**
  - $6.5 - $7.0
- **2012 ACTUAL\(^3\)**
  - $7.3

**ADJUSTED OTHER (INCOME)/DEDUCTIONS\(^5\) (in Millions)**

\[\begin{array}{cc}
800 & 810 \\
820 & 830 \\
840 & 850 \\
860 & 870 \\
880 & 890 \\
900 & 910 \\
920 & 930 \\
940 & 950 \\
\end{array}\]

- **2013 GUIDANCE\(^5\)**
  - APPROX. $900
- **2012 ACTUAL\(^2\)**
  - $835

**EFFECTIVE TAX RATE ON ADJUSTED INCOME\(^5\)**

\[\begin{array}{cc}
27.0 & 27.2 \\
27.4 & 27.6 \\
27.8 & 28.0 \\
28.2 & 28.4 \\
28.6 & 28.8 \\
29.0 & 29.2 \\
29.4 & 29.6 \\
29.8 & 30.0 \\
\end{array}\]

- **2013 GUIDANCE\(^5\)**
  - APPROX. 28.0\%
- **2012 GUIDANCE\(^5\)**
  - APPROX. 29.0\%
- **2012 ACTUAL\(^3\)**
  - 29.3\%

**REPORTED DILUTED EPS\(^6\)**

\[\begin{array}{cc}
1.25 & 1.30 \\
1.35 & 1.40 \\
1.45 & 1.50 \\
1.55 & 1.60 \\
1.65 & 1.70 \\
1.75 & 1.80 \\
1.85 & 1.90 \\
1.95 & 2.0 \\
\end{array}\]

- **2012 GUIDANCE\(^2,3\)**
  - $1.30 - $1.38
- **2013 GUIDANCE\(^4\)**
  - $1.50 - $1.65
- **2012 ACTUAL\(^3\)**
  - $1.94
1. Please refer to Pfizer’s 2012 Annual Report on Form 10-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this Annual Review.

2. At exchange rates that reflected a blend of the actual exchange rates in effect during the first nine months of 2012 and the mid-October 2012 exchange rates for the remainder of the year. Our 2012 guidance did not assume the completion of any business development transactions not completed as of September 30, 2012, including any one-time upfront payments associated with such transactions. It also excluded the potential effects of the resolution of litigation-related matters not substantially resolved as of September 30, 2012, except for charges for such matters that were recorded during the first nine months of 2012.

3. Revenues and expenses related to the Nutrition business as a discontinued operation were included for the full year in the guidance and through November 30, 2012 in actual results. The gain on the sale of the Nutrition business was not reflected in the Reported Diluted EPS guidance but is included in actual results for Reported Diluted EPS.

4. Our 2013 financial guidance is as of January 2013 and does not assume the completion of any business development transactions not completed as of December 31, 2012, including any one-time upfront payments associated with such transactions, and excluded the potential effects of the resolution of litigation-related matters not substantially resolved as of December 31, 2012. The exchange rates assumed in connection with the 2013 financial guidance are as of mid-January 2013.

5. “Adjusted Income” and its components and “Adjusted Diluted Earnings Per Share (EPS)” are defined as U.S. generally accepted accounting principles (U.S. GAAP) reported net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items. Adjusted Cost of Sales, Adjusted Selling, Informational and Administrative (SI&A), Adjusted Research and Development (R&D) expenses and Adjusted Other (Income) Deductions are income statement line items prepared on the same basis and, therefore, components of the overall adjusted income measure. As described in our Annual Report on Form 10-K for the year ended December 31, 2012, management uses adjusted income, among other factors, to set performance goals and to measure the performance of the overall company. Reconciliations of certain U.S. GAAP reported to Non-GAAP adjusted income and adjusted diluted EPS are provided in our Form 10-K for the year ended December 31, 2012. Adjusted income and its components and adjusted diluted EPS are not, and should not be viewed, as substitutes for U.S. GAAP net income and its components and adjusted diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, adjusted income and its components and adjusted diluted EPS are Non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

6. “Reported Net Income” is defined as net income attributable to Pfizer Inc. and “Reported Diluted EPS” is defined as net income attributable to Pfizer Inc. common shareholders.
ABOUT THIS REVIEW

This fully integrated Annual Review discusses many dimensions of our performance—financial, social and environmental—in one review. It demonstrates the integral relationship between our responsibilities as an enterprise and our core business strategies and their execution. It is produced for all of our stakeholders—patients, the medical community, investors, colleagues, customers and the public at large—to give an overall picture of how we are doing and, more importantly, how we are making progress toward our stated commitments.

SCOPE OF REPORTING

This review covers Pfizer’s worldwide business and provides information on our activities for the year ending on December 31, 2012. This review describes key dimensions of both the company’s financial and non-financial performance and includes updates on our products; our R&D pipeline; our commitment to quality, safety and high ethical standards; and our responsibilities to all stakeholders, starting with our patients. This review also describes critical challenges in society—from expanding access to health to our environmental impact—and our strategies for managing them.

GLOBAL REPORTING INITIATIVE SUSTAINABILITY REPORTING GUIDELINES

As global standards for integrated reporting do not exist, we considered the Global Reporting Initiative (GRI) Sustainability Reporting Guidelines (G3) in preparing this review. A comprehensive GRI Index is included in this report. We self-declare this review to GRI Application Level B.

CORPORATE RESPONSIBILITY MANAGEMENT

This review was developed by Pfizer’s Policy, External Affairs and Communications Group, whose leader is a member of the Executive Leadership Team and reports directly to the CEO. Corporate responsibility is embedded in our business strategy and vision, and many corporate responsibility issues are managed within our business units and functional groups to ensure thorough integration in all of our work. The Corporate Responsibility team sets the strategic direction for corporate responsibility at Pfizer and supports the integration of corporate responsibility throughout the company. The team is also responsible for Pfizer’s flagship global health philanthropic programs. Pfizer’s Corporate Responsibility team provides annual updates to Pfizer’s Board of Directors on progress in achieving corporate responsibility goals.
BOARD OF DIRECTORS

DENNIS A. AUSIELLO, M.D. (2,4,5,6)
Physician-in-Chief
Massachusetts General Hospital

M. ANTHONY BURNS (1,2,4,6)
Chairman Emeritus
Ryder System, Inc.

W. DON CORNWELL (2,3,4,6)
Founder and Retired Chairman and CEO Granite Broadcasting Corporation

FRANCES D. FERGUSSON, PH.D. (3,5,6)
President Emeritus
Vassar College

WILLIAM H. GRAY III (4,6)
Chairman
Gray Global Strategies, Inc.

M. ANTHONY BURNS (1,2,4,6)
Chairman Emeritus
Ryder System, Inc.

W. DON CORNWELL (2,3,4,6)
Founder and Retired Chairman and CEO Granite Broadcasting Corporation

FRANCES D. FERGUSSON, PH.D. (3,5,6)
President Emeritus
Vassar College

WILLIAM H. GRAY III (4,6)
Chairman
Gray Global Strategies, Inc.

HELEN H. HOBBS, M.D. (4,5,6)
Investigator
Howard Hughes Medical Institute

CONSTANCE J. HORNER (1,4,5,6)
Former Assistant to the President of the United States and Director of Presidential Personnel

JAMES M. KILTS (3,4)
Founding Partner
Centerview Capital

GEORGE A. LORCH (7)
Chairman Emeritus
Armstrong Holdings, Inc.

JOHN P. MASCOTTE* (4,5,6)
Retired President and CEO
Blue Cross and Blue Shield of Kansas City, Inc.

Suzanne Nora Johnson (2,3,6)
Retired Vice Chairman
The Goldman Sachs Group, Inc.

IAN C. READ (7)
Chairman of the Board and CEO

STEVEN W. SANGER (2,4,6)
Retired Chairman and CEO
General Mills

MARK TESSIER-LAVIGNE, PH.D. (5,6)
President
Rockefeller University

(1) Executive Committee
(2) Audit Committee
(3) Compensation Committee
(4) Corporate Governance Committee
(5) Regulatory and Compliance Committee
(6) Science and Technology Committee
(7) Lead Independent Director

* Will retire as a Board Member effective as of the April 2013 Annual Meeting
EXECUTIVE LEADERSHIP TEAM

IAN C. READ
Chairman of the Board and
Chief Executive Officer

OLIVIER BRANDICOURT, M.D.
President and General Manager
Emerging Markets and
Established Products

FRANK A. D'AMELIO
Executive Vice President
Business Operations and
Chief Financial Officer

MIKAEL DOLSTEN, M.D.
President
Worldwide Research &
Development

GENO GERMANO
President and General Manager
Specialty Care and Oncology

CHUCK HILL
Executive Vice President
Worldwide Human Resources

DOUG LANKLER
Executive Vice President
Chief Compliance & Risk Officer

FREDA C. LEWIS-HALL, M.D.
Executive Vice President
Chief Medical Officer

ANTHONY J. MADDALUNA
Executive Vice President / 
President, Pfizer Global Supply

LAURIE OLSEN
Executive Vice President
Strategy, Portfolio and 
Commercial Operations

AMY SCHULMAN
Executive Vice President and 
General Counsel 
Business Unit Lead, 
Consumer Healthcare

SALLY SUSMAN
Executive Vice President 
Policy, External Affairs 
and Communication

JOHN YOUNG
President and General Manager, 
Primary Care
Our businesses include five prescription-only biopharmaceutical businesses and Pfizer Consumer Healthcare. Primary Care, Specialty Care and Oncology are responsible for life-cycle management of in-line products and promising new therapies that have achieved “proof of concept” in our labs, while also ensuring that patient and customer needs inform the development of new medicines and vaccines.
Primary Care

Our solutions help patients and health care providers manage chronic, costly conditions, and are designed to improve outcomes and overall health. Through leadership in areas such as the management of pain and heart disease, our medicines treat conditions that account for a large and growing portion of the world’s health care costs. Our pipeline includes molecules with potential in women’s health, pain, cardiovascular and metabolic diseases, allergy and respiratory, and Alzheimer’s disease.

2012 HIGHLIGHTS

Eliquis (apixaban) gained approval to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation in the U.S., the 27 countries in the European Union, Canada, and Japan, and is under review in other countries. Eliquis, an oral Factor Xa inhibitor anticoagulant, has demonstrated superior risk reductions versus warfarin in three key outcomes of stroke and systemic embolism, major bleeding and all-cause death in patients with nonvalvular atrial fibrillation. In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize this oral anticoagulant, which was discovered by Bristol-Myers Squibb.

Lyrica (pregabalin) capsules CV received a new indication in the U.S. for the management of neuropathic pain associated with spinal cord injury. This is the fifth indication approved for Lyrica. Core indications for Lyrica are fibromyalgia and diabetic peripheral neuropathy, and Lyrica is the first indication approved for the management of neuropathic pain associated with spinal cord injury in the U.S.

Lyrica received regulatory approval in Japan for the additional indication of pain associated with fibromyalgia.

Integrated Health, Pfizer’s new approach to identifying innovative ways to partner with payers, providers and employers to improve patient outcomes, launched its first two products focused on the employer health and wellness market: KEAS, an online platform designed to engage employees around healthy behaviors; and the American Health Strategies Project, a tool designed to help demonstrate the costs of chronic diseases and highlight potential interventions to reduce costs and improve employee health outcomes.

KEY MEDICINES

- Celebrex (celecoxib)
- Chantix/Champix (varenicline)
- Eliquis (apixaban)
- Lyrica (pregabalin)
- Oxecta (oxycodone HCl)
- Premarin (conjugated estrogens)
- Pristiq (desvenlafaxine)
- Spiriva (tiotropium)
- Toviaz (fesoterodine)
- Viagra (sildenafil citrate)
Specialty Care

Featuring a robust portfolio of medicines, we are a leader in vaccines and the treatment of inflammation, two important areas of innovation and growth in biomedical science. We understand the devastating impact of rare diseases on patients and are dedicated to addressing these serious unmet medical needs by seeking to discover, develop and deliver treatments for them. Our medicines help address potentially life-threatening and debilitating diseases at every stage of life.

2012 HIGHLIGHTS

The U.S. Food and Drug Administration approved Xeljanz (tofacitinib) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Prevenar 13 received regulatory approvals for the adult indication in more than 80 countries.

Initiated the first Phase III study for our investigational vaccine, rLP2086, part of the largest vaccine clinical development program to date in invasive meningococcal B disease.

Initiated Phase III studies for tofacitinib in ulcerative colitis.

Launched Vyndaqel (tafamidis) in seven countries in the EU, including Portugal, Germany, Austria, Luxembourg and Sweden.

Launched BeneFIX (coagulation factor IX (recombinant)) 3000 IU dosage and new Xyntha (antihemophilic factor (recombinant), plasma/albumin-free) dosage sizes.

Celebrated anniversaries: 15 years for BeneFIX (coagulation factor IX (recombinant)); 10 years for Rebif (interferon beta-1a) and the MS Lifelines Support Center.
Oncology

Our Oncology Business Unit remains dedicated to more targeted, rational and efficient drug development to help improve the outlook for cancer patients worldwide. In addition to introducing three new compounds in the U.S. in just over a year, and recently announcing EU marketing authorization for Inlyta and EU conditional marketing authorization for Xalkori, the Oncology unit has a promising late-stage pipeline, including dacomitinib and inotuzumab ozogamicin, being studied in non-small cell lung cancer and non-Hodgkin’s lymphoma, respectively. Additionally, Pfizer continues to prioritize our early portfolio and rigorously assess the number of molecules in development to focus on those that we believe hold the greatest potential for patients.

2012 HIGHLIGHTS

In January 2012, Inlyta (axitinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy. Inlyta also was approved this year in the European Union and a number of countries including Japan, Switzerland, Canada, Australia and Korea.

In September 2012, Bosulif (bosutinib) became the third new medicine from our Oncology pipeline to be approved by the U.S. FDA in 13 months, and the first therapy in Pfizer’s growing hematology portfolio to receive FDA approval.

Xalkori (crizotinib) was selected as a finalist in the 2012 Most Innovative Product of the year award competition, chosen by a group of industry experts. The pivotal Phase III PROFILE 1007 data, presented at the European Society for Medical Oncology, demonstrated that Xalkori is superior to standard chemotherapy in prolonging progression free survival in patients with previously-treated ALK-positive advanced non-small cell lung cancer (NSCLC). These data established Xalkori as a standard of care for this patient population. Xalkori also has received conditional marketing authorization in the EU for the treatment of adults with previously-treated ALK-positive advanced NSCLC.
Emerging Markets

Emerging markets offer opportunities for Pfizer to reach more patients around the world. A leader in these markets, we bring our innovative and high quality medicines to over 75 emerging countries. To meet patients’ diverse needs, our Emerging Markets unit offers our Primary Care, Specialty, Oncology, Vaccines and Established Products portfolios. While core brands have helped Pfizer reach more patients in the past and are a cornerstone of continued expansion, Established Products provide greater choice and affordability for patients in emerging markets.

2012 HIGHLIGHTS

In 2012, we successfully started the launches of Xalkori (crizotinib), Inlyta (axitinib) and Prevenar 13 Adult in emerging markets. We also achieved the delivery of 500 million doses of Prevenar 13.

As a leading multinational pharmaceutical company and the leader in cardiovascular disease management and treatment in China, Pfizer has been working with the Ministry of Health, the Cardiovascular Physician Branch of the Chinese Medical Doctor Association and the Stroke Prevention and Control Society of the Chinese Preventive Medicine Association on a “China Vascular Health Project.” The project was initiated and led by the SPCS and launched in the beginning of 2012. It has adopted a multi-pronged approach to address the huge unmet need and key challenges, such as disease awareness among patients, diagnosis accuracy, treatment efficiency and effectiveness, long-term disease management and prevention.

To date, the project has achieved significant outcomes, including screening more than 502,000 patients in almost 500 hospitals in 95 cities throughout China. Forty-six percent of the screened population were found to have dyslipidemia and this project helped more than 77 percent of these patients find treatment options. Cardiovascular disease has become an increasingly serious public health and socio-economic problem in China, with more than 270 million dyslipidemia patients and a diagnosis rate that is lower than 10 percent.

Pfizer has established more than 45 partnerships to support health care priorities around the world. Partnerships include 20 national immunization programs and participation in the GAVI Alliance, which provides life-saving vaccines to people in developing countries.

Our broader strategy in the world’s largest emerging markets, such as Brazil, Russia, India, China, Mexico and Turkey, includes offering affordable, high quality medicines in order to reach more patients. For example, our partnership with Teuto in Brazil has yielded branded and generic versions of Viagra and Lipitor as well as anti-inflammatory and anti-depression medications. The joint venture between Hisun and Pfizer aims to strengthen the ability of both companies to address health care needs in China and reach more patients with high quality and low cost medicines in the branded generics arena.
Established Products

We offer growth opportunities for Pfizer to reach more patients in the developed world with Pfizer-originated medicines that have lost or are close to losing patent protection and with non-Pfizer-originated medicines secured through licensing or acquisitions. The off-patent pharmaceutical field is one of the fastest-growing segments in the global pharmaceutical market. Currently, we offer over 600 off-patent Pfizer legacy brands and other generic products, backed by the highest quality standards and consistency of supply.

2012 HIGHLIGHTS

Pfizer has acquired NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system disorders. NextWave is the developer of Quillivant XR (methylphenidate HCl) for extended-release oral suspension, CII, the first once-daily liquid medication approved in the U.S. for the treatment of ADHD, and holds exclusive North American commercialization rights to Quillivant XR. This recently approved medicine was launched in the U.S. in early 2013.

We launched Elelyso (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease. Elelyso is the first FDA-approved plant cell-based ERT for Gaucher disease.

Pfizer has established an exclusive long-term strategic collaboration with Mylan to develop, manufacture, distribute and market generic drugs in Japan, the second largest pharmaceutical market in the world, where there is an ever-growing demand for high quality generics.

Pfizer has created a Loss Of Exclusivity (LOE) Center of Excellence within the Established Products Business Unit to offer brand teams that are facing similar LOEs the expertise to successfully navigate brand patent expirations. The Center offers an “LOE Roadmap,” a detailed handbook for teams that are developing strategies to maximize the value of their products both before and after patent loss, and an LOE Library, which contains examples of strategic planning documents, market research and promotional materials.

Pfizer has created a Loss Of Exclusivity (LOE) Center of Excellence within the Established Products Business Unit to offer brand teams that are facing similar LOEs the expertise to successfully navigate brand patent expirations. The Center offers an “LOE Roadmap,” a detailed handbook for teams that are developing strategies to maximize the value of their products both before and after patent loss, and an LOE Library, which contains examples of strategic planning documents, market research and promotional materials.

80% of prescriptions in the U.S. are filled with generics and other off-patent medicines.

50% of global pharmaceutical sales by 2020 will be off-patent medicines and their generic equivalents.

**KEY MEDICINES**

- Effexor (venlafaxine hydrochloride)
- Fragmin (dalteparin sodium)
- Lipitor (atorvastatin)
- Norvasc (amlodipine besylate)
- Relpax (eletriptan HBr)
- Zosyn/Tazocin (piperacillin/tazobactam)
Consumer Healthcare

We meet consumers’ health and wellness needs around the world through our science-based, differentiated self-care solutions. We are ranked fifth globally among multinational, branded consumer healthcare companies, and second in our largest markets—the U.S., Canada and China. We compete in three of the top five categories in the global over-the-counter (OTC) industry. We are the only company with two of the top 10 global OTC brands—Advil and Centrum.

**2012 HIGHLIGHTS**

We continued to outpace global OTC growth in 2012.

Through our acquisition of Ferrosan, we expanded our product offerings in the fast-growing probiotics and Omega-3 categories, and extended our geographic footprint into the Nordic markets, Russia and other Eastern European markets.

Through the acquisition of Alacer, we added a leading vitamin C supplement, Emergen-C, to our dietary supplements portfolio.

Another major business development in 2012 was the acquisition from AstraZeneca of exclusive, global over-the-counter marketing rights for Nexium. Nexium is the fifth-best selling prescription medicine and a leading prescription remedy to treat the symptoms of gastroesophageal reflux disease (GERD). The gastrointestinal health market is the fourth-largest OTC category.

Advil maintained its market-leading position in a number of key geographies, including the U.S. and Canada, with sustained revenue growth for the year.

We expanded the Centrum franchise through the accelerated launches of Centrum Gender and Centrum Cardio/ Centrum Control into many markets across Europe and Latin America.
The world is our market. Every part of our global enterprise is focused on the people we can help through our products, knowledge and expanding portfolio, as we strive to meet humanity’s growing medical and personal health care needs.

**UNITED STATES**  
**Acquiring Strong Product and Expertise**

Pfizer acquired NextWave Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system disorders. The agreement includes Quillivant XR (methylphenidate HCl), the first once-daily liquid ADHD treatment in the United States. Pfizer launched Quillivant XR in the U.S. in January 2013—providing patients and their caregivers a new treatment option for the disorder.

**UNITED KINGDOM**  
**Embedded Collaboration in Academia**

Pfizer and the Cardiovascular Epidemiology Unit at the University of Cambridge in the U.K. have established a collaboration that strives to develop new medicines for cardiovascular disease. Pfizer brings a strong precision medicine focus to the collaboration, which has Pfizer scientists and University of Cambridge researchers working side by side. This collaboration with some of Europe’s top experts in population health sciences furthers Pfizer’s strategy to tap into leading scientific minds and resources in academia.

**FRANCE**  
**Focused Research Partnerships**

Pfizer and France’s Institut du Cerveau et de la Moelle Épinière (ICM Brain and Spine Institute) are embarking on a three-year scientific collaboration to investigate the fundamental mechanisms of certain neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s diseases. Based in Paris, ICM is a major scientific center, composed of more than 500 researchers and physicians focused on fundamental and translational neuroscience research, with a strong emphasis on industry partnerships.
**CHINA**

**Branded Generics in China**

Pfizer and Hisun, a leading China-based pharmaceutical company, have launched Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture to provide high quality, affordable branded generic medicines for patients in China and other global markets. Hisun-Pfizer is expected to develop, manufacture and commercialize a range of off-patent pharmaceutical products.

---

**JAPAN**

**Branded Generics in Japan**

Pfizer and Mylan, the world’s third-largest generics and specialty pharmaceuticals company, have forged an exclusive strategic collaboration to drive growth of the generics business in Japan, the second-largest pharmaceutical market in the world. The collaboration builds on Pfizer’s already-strong commercial presence and Mylan’s reputation for global quality, manufacturing and supply chain reliability for its generic medicines.

---

**AUSTRALIA**

**Innovation in Sterile Injectables**

Regulators in Europe have approved the use of docetaxel, a sterile injectable developed by Pfizer Global Supply in Perth, Australia, for the treatment of breast, ovarian, prostate and non-small cell lung cancer. Docetaxel features a single-vial preparation manufactured in plastic Cytosafe vials, which offer significant safety benefits over a competing innovator’s two-stage injection system. Docetaxel is also stable at room temperature and has a commercially viable shelf life of at least 24 months.
STRONGER BUSINESS

COLLEAGUES

Colleagues at Pfizer are committed to building an organization that encourages the sharing of diverse ideas, taking accountability, acting with an entrepreneurial spirit and giving our best every day. Personal accountability and candid debate — we refer to this as Straight Talk — are core to our ownership culture and foundational to the way we need to work. Our ownership culture is what will differentiate us from our industry competitors.

“OWN IT!”

OWN IT!

“We must try new approaches and think differently. Innovation and accountability need to happen right here, with me.”

NIVIN PEI
Director, Global Technology Services
Pfizer Global Supply
As part of our cultural transformation, colleagues participate in an annual survey, PfizerVoice. In 2012, more than 86,000 colleagues globally provided feedback about Pfizer’s culture and how we are performing as an organization. The survey measures engagement levels and helps assess our progress in achieving the key dimensions of high performing organizations.

OWN IT!

“My team is Pfizer, and we’re all about results. It’s up to each of us to deliver on our commitments.”

KAREN SANSONE
Senior Director, Business Technology

OWN IT!

“How well we do, as a business and as a force for good in this world, is up to us. That’s how I approach every day.”

ZOE ZAVATTIERI
Sales Director
Established Products Business Unit—U.S. Brands
Our recruitment brand, “Many Paths One Goal,” continues to focus on attracting top talent around the world to the varied career opportunities that exist within Pfizer. Career paths range across general management, research and development, manufacturing, and enabling functions, but our goal is the same. By owning our careers at Pfizer, we make the world a healthier place.
Pfizer colleagues around the globe have embraced our Diversity & Inclusion Strategy, which focuses on increasing access to diverse talent pools, engaging and developing diverse talent, and advancing the business.

**DIVERSITY**

"Through the disAbility Pfizer Colleague Council, we are working to expand our access to diverse talent, including hosting Disability Mentoring Day, a longstanding partnership that Pfizer has with the Office of the Mayor of New York City."

**SEAN HUDSON**
Director, Human Resources
Worldwide Research and Development

**DIVERSITY**

"We are making an impact through our innovative Get Old partnership with SAGE, the oldest and largest services and advocacy group for LGBT seniors in the U.S."

**ANTHONY PALKOVIC**
Director, Worldwide Commercial Development, Business Development & Strategy

**DIVERSITY**

"As a co-chair of OPEN-NY, I have the opportunity to shape the policies, strategies and partnerships that enhance Pfizer’s culture and our reputation among the LGBT community."

**ZAK KARIM**
Director, Human Resources
Worldwide Research and Development
At Pfizer, we understand that good corporate governance is essential to our standing as a trusted member of society, and we conduct ourselves accordingly.

**Board of Directors**

Pfizer’s Board of Directors is responsible for the oversight of management, including the overall strategic direction of the company and for the company’s policies on governance, executive compensation, transparency and compliance.

Read more about our Board of Directors [here](#).

**Compliance**

We believe that compliance with all applicable laws is integral to our ability to serve society. We train colleagues extensively in compliance and have an organizational structure designed to ensure good oversight of our colleagues, vendors and business partners.

Read more about our Compliance [here](#).

**Ethical Sales and Marketing**

We are committed to promoting our products responsibly, educating patients and providers about their appropriate use, and reporting about our business practices in a fashion that promotes transparency.

Read more about our Ethical Sales and Marketing [here](#).

**Disclosing Payment to Health Care Professionals**

We do not pay health care professionals for prescribing our medicines or as an inducement for promoting our products. We believe it is appropriate and ethical to fairly compensate health care professionals for work they do on our behalf.

Read more about our Disclosing Payment to Health Care Professionals [here](#).

**Direct-to-Consumer Advertising in the U.S.**

Our strict internal standards, going beyond compliance with the law, have been developed to ensure that the information we share with patients is scientifically sound, balanced, easy to understand and helpful in encouraging them to consult with a health care professional.

Read more about our Direct-to-Consumer Advertising [here](#).

**Human Rights**

Pfizer strives to uphold human rights in all our business activities. We also work to advance human rights by working to improve the health of people around the world.

Read more about our Human Rights [here](#).
Partnering to Expand R&D Impact

External collaboration is critical to advancing our R&D strategy and expediting new breakthroughs for patients

OWNING COLLABORATION

Centers for Therapeutic Innovation

Pfizer’s Centers for Therapeutic Innovation (CTI) enable us to partner more closely with academic scientists located at major biotech hubs in the U.S., all in an effort to accelerate the translation of emerging science into new therapies. CTI combines the research expertise of academic experts in disease, targets and patient populations with Pfizer’s R&D knowledge, resources and development capabilities. CTI’s innovative business model allows academic scientists to share more fully in the value of their science and positions Pfizer to potentially enrich our R&D pipeline with innovative next generation therapeutics.

National Center for Advancing Translational Sciences

Pfizer is a pioneering partner in the National Center for Advancing Translational Sciences (NCATS), the newest program of the U.S. National Institutes of Health (NIH). NCATS provides a collaborative program to match academic researchers with dozens of pharmaceutical industry-owned molecules. A key step forward for the R&D ecosystem, this emerging meta-collaboration among government, academia and industry focuses on a portion of the therapeutic pipeline that traditionally has been difficult for academic researchers to access: compounds that already have cleared safety testing in humans.

Industry partners will retain ownership of their compounds, while academic partners will own any intellectual property they discover using these compounds, along with the right to publish their results.

Some compounds are not effective for their initial intended use, but additional research may yield different therapeutic uses. Examples include sildenafil, which was originally studied as a potential angina treatment, but went on to be developed as Viagra for erectile dysfunction and then repurposed as Revatio for pulmonary arterial hypertension.

COLLABORATING ACROSS ALL BOUNDARIES

Pfizer has a robust internal pipeline of product candidates across our key therapeutic focus areas, all of which are rooted in leading-edge science in disease biology. Pfizer’s 10 in-house research units are complemented by a wide range of collaborators outside the company. Our new, more expansive approach to external collaboration is essential to our R&D strategy—forging partnerships that connect the assets and capabilities of different organizations and sectors to speed the development of new medicines for patients.
Cystic Fibrosis Foundation Therapeutics, Inc.

Cystic Fibrosis Foundation Therapeutics, Inc., the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, has greatly expanded its research collaboration with Pfizer, agreeing to invest up to approximately $58 million to speed potential therapies that target the most common underlying causes of cystic fibrosis. The new six-year pre-clinical research program strengthens Pfizer’s position in developing therapies that help “correct” the action of mutated proteins and is designed to advance one or more drug candidates into the clinic. Such innovative collaborations between industry and patient organizations are seen as increasingly critical in expediting the translation of science into potential new treatments.

Duke University: Exploring Insulin Resistance

Pfizer entered into collaboration with Duke University’s Stedman Center to enhance our understanding of the mechanisms by which insulin resistance develops in humans. The partnership focuses on identifying the pathways underlying the development of diabetes by leveraging the Center’s established technology platforms and deep understanding of metabolic pathways. These insights into the biology of diabetes support the research and development of compounds that target the underlying causes of the disease.

Nodality: Precision Medicine R&D for Lupus

Nodality and Pfizer have entered into a strategic collaboration for the use of Nodality’s proprietary Single Cell Network Profiling (SCNP) technology as a Precision Medicine tool for the development of Pfizer compounds to treat autoimmune diseases. Precision Medicine has been widely adapted in oncology drug development, and there is considerable optimism that these principles can be applied to other disease areas. This multiyear, collaborative effort will initially focus on lupus, including characterizing mechanisms of action, disease analysis and drug profiling. Pfizer Venture Investments has been an investor in Nodality since 2008.

Transcelerate: Drug Development Solutions

Pfizer is a founding member of TransCelerate BioPharma, a nonprofit consortium formed by leaders in our industry to accelerate the development of new medicines. Joining us in the initiative are Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Roche and Sanofi.

This cross-industry initiative is dedicated to identifying and solving common drug development challenges, beginning with clinical study execution, with the end goals of improving the quality of clinical studies and bringing new medicines to more patients more quickly. The five initial projects are: development of a shared user interface for investigator site portals; mutual recognition of study site qualification and training; development of risk-based site monitoring approach and standards; development of clinical data standards; and establishment of a comparator drug supply model.
INNOVATIVE SCIENCE

Advancing Our Pipeline

A Focused Portfolio of Promising Drug Candidates

Our programs in development include potential treatments for autoimmune diseases such as inflammatory bowel disease, lupus, cardiovascular disease, diabetes, cancer, neurological diseases and pain, as well as vaccines for meningococcal B disease in adolescents and for Staphylococcus aureus.

View the latest pipeline on pfizer.com

PROGRAMS IN CLINICAL TRIAL AND REGISTRATION

As of February 28, 2013

- DISCOVERY PROJECTS: 29
- PHASE I: 29
- PHASE II: 25
- PHASE III: 17
- IN REG.: 7
- TOTAL: 78
Creating a Robust and Sustainable Innovative Core

We continue to transform our R&D approach and capabilities with strategic choices that build a sustainable engine for innovation over the long term, while at the same time ensuring we execute effectively on our near-term pipeline priorities.

ADVANCING A DIFFERENTIATED PIPELINE — OUR R&D PRIORITIES

Pfizer has established three R&D priorities, unfolding over time, to focus on advancing a differentiated pipeline of medicines and vaccines.

Underlying our choices is a focus on increasing differentiation and innovation and improving R&D productivity and return on investment over the long term, while at the same time seeking to ensure we execute effectively on our near-term pipeline priorities. Two years after launching a comprehensive R&D turnaround effort, we are seeing positive indicators, with a robust portfolio grounded in rigorous decision making and an ownership culture.
1. Deliver the Portfolio

First and foremost, we are concentrating internal efforts where we believe we can deliver the greatest medical and commercial impact in areas of significant patient need. Over the last year, Pfizer has gained momentum in our late-stage pipeline with key regulatory approvals for important new medicines, including Eliquis (apixaban) for stroke prevention in nonvalvular atrial fibrillation, Xeljanz (tofacitinib), a first-in-class JAK inhibitor for moderate-to-severe rheumatoid arthritis, and the oncology compounds Inlyta (axitinib) and Basulif (bosutinib).

Pfizer is advancing a solid late-stage pipeline, including a number of Phase III programs in areas of critical patient need, such as:

- **Vaccines**: To prevent Meningitis B in adolescents.
- **Breast Cancer**: Palbociclib (PD-991) for certain breast cancer patients with limited treatment options.
- **Blood cancer**: Inotuzumab ozogamicin, an antibody drug conjugate for certain types of lymphoma and leukemia.
- **Autoimmune disease**: Xeljanz (tofacitinib) in psoriasis and ulcerative colitis.

2. Innovate New Capabilities That Position Us for Leadership

Pfizer is focused on innovative capabilities that can position the company for long term competitive advantage. This includes the significant expansion of our vaccine development program, which now includes investigational first-in-class therapeutic and prophylactic vaccines targeting smoking cessation and deadly hospital-acquired infections. It also includes a leading platform in next-generation antibody drug conjugates (ADCs), which are targeted treatments for cancer that include an antibody and cancer cytotoxic in one medicine. Pfizer has cutting-edge small and large molecule technology capabilities that position us to develop fit-for-purpose optimized medicines for patient needs.

In addition to scientific capabilities Pfizer is at the forefront of innovating novel open-innovation models such as the CTIs, where Pfizer scientists work in real time with academic scientists to expedite the translation of science into medicine.

Key early-to-mid-stage clinical programs that reflect our new capabilities include:

- **Cardiovascular disease**: An optimized antibody targeting PCSK9 for high LDL cholesterol
- **Vaccines**: Therapeutic vaccine for smoking cessation, and prophylactic vaccines targeting two common and deadly hospital-acquired infections caused by Staph. aureus and C. difficile bacteria
- **Pain**: New family of candidates targeting ion channels with important implications in pain
- **Oncology**: Our first next-generation ADC, rooted in novel science on cancer stem cells
- **Diabetes**: Tissue-distributed small molecule glucokinase inhibitors designed to help patients with glycemic control without causing long term complications
- **Autoimmune disease**: Novel antibodies targeting inflammatory bowel disease (IBD) and lupus
- **Rare disease**: Antibody targeting new pathways for Duchenne’s muscular dystrophy, a debilitating and deadly genetic disease in children

3. Build the R&D Ecosystem of the Future

We are moving toward a much more networked R&D model—shaping how biopharmaceutical innovation will be done. The R&D ecosystem of the future will draw on the total capabilities in the biomedical community, reducing silos and increasing productivity.

Critical to this new ecosystem is optimizing the promise of Precision Medicine, an approach to discovering, developing and commercializing medicines that we believe will deliver superior clinical outcomes in complex diseases, identify patient populations that are most likely to respond to our medicines and expedite the timelines for drug development.
Ensuring Integrity in Clinical Trials

We work to help ensure that all our clinical trials, wherever they take place, are conducted to the same high ethical standards and comply with applicable local laws and federal regulations to ensure the rights and welfare of our clinical trial participants around the world are fully protected. We recently re-engineered our clinical trial process to further enhance our capabilities in these areas, in particular by implementing quality management principles (such as quality by design) into these processes, and our vigilance and oversight of contract research organization partners and clinical trial physician investigators, who are actively involved in the development of our new medicines. As part of this quality process, we conduct inspections of these sites and studies to help ensure patient safety, data integrity, protocol adherence and regulatory compliance.

Clinical Innovation Roadmap

We launched Clinical Innovation in 2011 to provide focus and discipline in our initiatives to reverse the increasing time, cost and complexity of clinical trials across the industry. As an early mover defining the field, we are positioned as a leader driving the re-invention of clinical research for Pfizer and the R&D ecosystem.

Our vision for that ecosystem includes research participation made easier for patients and providers, enabling every health care interaction to serve as an opportunity to inform our medical product development.

Pfizer Clinical Innovation develops, tests and scales new approaches to understand the efficacy and safety of our investigational medicines, drawing from tools such as mobile health, social media and health information technology. Clinical Innovation also leads collaborations with other stakeholders to work together to fix shared clinical research challenges. Collaboration examples include: TransCelerate BioPharma, a novel partnership of 10 major biopharmaceutical companies developing shared solutions, and the Partnership to Advance Clinical Electronic Research, an initiative aligning pharmaceutical companies with New York-based medical centers to improve the use of electronic health records in clinical research.
INNOVATIVE SCIENCE

LEADING MEDICINES

Noteworthy in 2012

Xeljanz

Xeljanz (tofacitinib) is the first new oral disease-modifying antirheumatic drug approved for rheumatoid arthritis in more than ten years and the first rheumatoid arthritis treatment in a new class of medicines known as Janus kinase (JAK) inhibitors. Unlike biologic therapies, which work outside the cell, Xeljanz targets the inflammation associated with rheumatoid arthritis from inside the cell. Specifically, Xeljanz inhibits the JAK pathways, which are signaling pathways inside cells that are used by pro-inflammatory cytokines (proteins that facilitate communication between cells). Approved in the U.S. for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, Xeljanz is currently under review by several regulatory agencies around the world, including in Europe and Japan.

Bosulif

Bosulif (bosutinib) is for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy. Once-daily Bosulif was studied in a broad range of patients with CML, including CML patients treated with imatinib followed by a second-generation tyrosine kinase inhibitor. Bosulif addresses an unmet need in the CML treatment landscape.

Eliquis

Eliquis (apixaban) gained approval to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation in the U.S., the 27 countries in the European Union, Canada, and Japan, and is under review in other countries. Eliquis, an oral Factor Xa inhibitor anticoagulant, has demonstrated superior risk reductions versus warfarin in three key outcomes of stroke and systemic embolism, major bleeding and all-cause death in patients with nonvalvular atrial fibrillation. In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize this oral anticoagulant discovered by Bristol-Myers Squibb.

Inlyta

Inlyta (axitinib) is indicated for the treatment of advanced kidney cancer when one prior drug treatment for this disease has not worked or has stopped working. It is the first treatment to demonstrate superior progression-free survival in a Phase III study compared with sorafenib in second-line advanced kidney cancer. Since its approval, Inlyta has established its utility in this setting, where it is an important treatment option for many patients with advanced renal cell carcinoma after failure of one prior systemic therapy.

Quillivant XR

Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, is the first once-daily liquid medication approved in the U.S. for the treatment of attention deficit/hyperactivity disorder (ADHD). This recently approved medicine is expected to be available in pharmacies in the U.S. in early 2013. With the acquisition of NextWave Pharmaceuticals in 2012, Pfizer gained exclusive North American rights to market Quillivant XR.

For more information on any of these medicines, visit Pfizer Pharmaceutical Products.
Our Top 10 Best Selling Medicines in 2012

Lyrica
(pregabalin)
$4,158 million

Lipitor
(atorvastatin)
$3,948 million

Enbrel
(Outside the U.S. and Canada)
(etanercept)
$3,737 million

Prevnar 13/Prevenar 13
(pneumococcal polysaccharide conjugate vaccine)
$3,718 million

Celebrex
(celecoxib)
$2,719 million

Viagra
(sildenafil)
$2,051 million

Norvasc
(amlodipine besylate)
$1,349 million

Zyvox
(linezolid)
$1,345 million

Sutent
(sunitinib malate)
$1,236 million

Premarin Family
(conjugated estrogens)
$1,073 million

For more information on any of these medicines, visit Pfizer Pharmaceutical Products.
INNOVATIVE SCIENCE

LEADING CONSUMER HEALTHCARE PRODUCTS

Familiar Around the World

Pfizer Consumer Healthcare’s products include OTC medicines, supplements and other treatments that are top sellers in their categories and household names for consumers around the world.
Advil is a trusted and effective OTC pain reliever for more than 25 years for millions of consumers. Advil is one of Pfizer’s billion-dollar brands and the No. 1 selling branded OTC analgesic in the world. In 45 countries, Advil helps consumers treat headaches, backaches, muscle aches, minor arthritis and other joint pain, and the aches and pains of the common cold. In 2012, Children’s Advil enhanced its position in the U.S. and Canada, becoming the No. 1 selling OTC pediatric brand in those markets. In Australia, we launched the Advil Children’s Pain & Fever line. In a number of Latin American markets, we extended the brand into the cold/flu segment. This year also brought substantial success for Advil Migraine, which has gained additional distribution at key retailers.

Learn more at advil.com
Caltrate is the No. 1 selling brand of calcium supplements in the U.S. and China. Globally, Caltrate is sold in 57 countries. In the U.S., we launched a new Caltrate formula in 2012 with double the amount of vitamin D3, which helps aid in the absorption of calcium—a higher amount of vitamin D3 than any other leading brand. Because bone is composed of two-thirds calcium and one-third collagen, healthy bones require both calcium and collagen for resiliency—a fact Caltrate has highlighted. The Caltrate 600+D Plus Minerals formulation, which contains calcium and vitamin D, plus extra minerals, helps to stimulate collagen production and delivers bone health. Caltrate is available in four different formulas and different forms to suit individual consumer needs.

Learn more at caltrate.com
Centrum

Centrum is the No. 1 selling brand of multivitamins in the world, sold in 86 countries, and the No. 1 doctor-recommended multivitamin brand in the U.S. Centrum provides a range of scientifically advanced multivitamins for adults and children that help fill dietary gaps and support important life benefits. In addition to Centrum and Centrum Silver, there are the following Centrum Specialist products in the U.S.: Energy, Heart, Vision and Prenatal. In 2012, we launched Centrum Gender—multivitamins specially designed to support men’s and women’s unique health needs—in Europe, Centrum Cardio/Centrum Control in Brazil and Taiwan, and Centrum Flavor Burst, a chewable adult multivitamin, in the U.S. Additionally, our Centrum Silver multivitamin was used in the Physicians’ Health Study II, a landmark 12-year study that evaluated the long-term benefits of taking multivitamins for men age 50 and older. The quality of Centrum multivitamins, among other factors, led the study investigators to use Centrum Silver as the multivitamin for the duration of the study.

Learn more at centrum.com
ChapStick

The leading lip care brand in the U.S., ChapStick is sold in 25 countries globally. Some of consumers’ favorite ChapStick products include Moisturizer, Classic Cherry and Classic Original. With a history of more than 125 years, the brand continues to evolve, incorporating new technologies to meet consumer demands for a product that replenishes, rehydrates and protects lips while providing great taste.

Learn more at chapstick.com
Emergen-C

A leading health and wellness lifestyle brand, Emergen-C features vitamin C in vitamin drink mixes and now a liquid concentrated shot. Through its 30 years on the market in the U.S., Emergen-C has built a loyal customer base. It is sold in more than 15 flavors, including top sellers Super Orange and Raspberry. Specialty formulas include Emergen-C Immune+ System Support, Joint Health, Heart Health, Vitamin D & Calcium and Emergen-C Multi-Vitamins.

Learn more at emergenc.com
Robitussin

The leading doctor-recommended OTC cough medicine brand in the U.S., Robitussin has been providing effective relief from cough and cold symptoms for more than 50 years. In 2012, the brand partnered with WebMD, the No. 1 online source in the U.S. for health information, to educate consumers about treating their coughs. Worldwide, Robitussin is the No. 3 branded cough remedy and is available in 41 countries. In addition to an extensive lineup of liquid cough and cold products, Robitussin Day & Night Cold + Flu products are also available in liquid-filled capsules. These products provide multisymptom relief of cough, nasal congestion, headache and sore throat in a convenient liquid-filled capsule form.

Learn more at robitussin.com
ThermaCare

Available in 12 countries, ThermaCare Heatwraps deliver heat that penetrates deep, warming the muscle right where it hurts—to relax, soothe and unlock tight muscles. In 2012, tapping into new channels available by virtue of the Ferrosan acquisition, ThermaCare products were launched in Denmark and Finland. ThermaCare HeatWraps have transformed the field of heat therapy by making it portable, safe and long-lasting. ThermaCare HeatWraps keep on working even after a person takes them off—totaling up to 16 hours of back pain relief.

Learn more at therma-care.com
INNOVATIVE SCIENCE

ENSURING GLOBAL SUPPLY

Produced to the Highest Standards

We strive to ensure that all Pfizer products are always available when needed.

ENVIRONMENT, HEALTH AND SAFETY IN THE SUPPLY CHAIN

At Pfizer, responsible supply chain management is central to how we do business. We operate within a framework of principles aligned with ethical, social and environmental responsibilities to help ensure the sustainability of our business and the communities in which we operate. To that end, an external supply team oversees efforts to ensure that our chemical and biological product suppliers manage environment, health and safety (EHS) risks. We recently partnered with the Institute of Sustainable Communities, an organization committed to advancing sustainability in developing countries through education and training, and we participate in the industry-wide Pharmaceutical Supply Chain Initiative.

Click here for more information about EHS within our supply chain.

Pfizer is committed to responsible supply chain management. To learn more, please see:

Supplier Conduct Position
Supplier Conduct Principles

SUPPLIER ONSITE ASSESSMENTS COMPLETED BY PFIZER’S EHS EXTERNAL SUPPLY TEAM IN 2012

There was a 30% reduction in EHS supplier onsite assessments from 2011 to 2012 due largely to the use of a new risk priority ranking tool.

OUR GLOBAL SUPPLY CHAIN

Pfizer products are produced to the highest standards, in full compliance with all applicable legal requirements. We supply products from both our internal manufacturing sites and a network of external partners. External partners are selected based on their ability to reliably supply quality product at a competitive cost. We apply rigorous controls to assure quality across the entire supply chain.

3,000+
Formulations

175
Markets

> 150
Market Distribution & Logistics Center Operations Globally

500+
Suppliers

84*
Manufacturing Sites

*Zoetis sites (formerly Pfizer Animal Health) are included.
GREATER IMPACT

EXPANDING ACCESS TO HEALTH

Building Sustainable Solutions to Expand Access

We are committed to bringing more medicines to more people and helping to improve health around the world. Our efforts are focused on building sustainable solutions to expand access to medicines and health care for underserved patients worldwide. We continue to explore models and approaches that are tailored to the needs of patients in different geographies with different needs.

It is often suggested that the price of medicine and enforcement of intellectual property rights are the main barriers to access to medicines in poor populations. Access to medicines is a complex issue, with the greatest impact coming from lack of health care infrastructure. We believe that protection of intellectual property and sustainable pricing are essential to our ability to discover and develop new medicines, and bring them to patients in need. Given the complexity of access issues and the need for a holistic approach to solving them, we work closely with governments and other stakeholders to address health care challenges and improve health around the world. We are also taking innovative approaches to pricing, including tiered pricing both across and within countries.
COMMERCIAL STRATEGIES

Developing Viable Business Models to Serve the Underserved

We are developing a portfolio of innovative business approaches and models as part of our strategy to increase access to our medicines and improve health care for underserved populations in both developed and developing countries. We are also taking innovative approaches to pricing in various markets, including tiered pricing both across and within countries, and portfolio offerings that address and balance customers’ cost sensitivities.

Providing Important Medicines Through Institutional Buyers

We work closely with global institutional buyers who purchase medicines for the neediest of patients. For example, Pfizer has long-standing business partnerships with both the U.S. Agency for International Development and the United Nations Population Fund to make our injectable contraceptive, Depo-Provera, available to women all across the globe, from sub-Saharan Africa to Southeast Asia to Latin America. We are working to expand our relationship with such institutional buyers to make a broad portfolio of our medicines accessible to as many low income patients as possible.
R&D PARTNERSHIPS

Partnering to Advance R&D for Diseases of the Underserved

Pfizer is committed to and collaborating on developing effective treatments for diseases that disproportionately affect the underserved, including HIV/AIDS, tuberculosis and otherwise neglected tropical diseases.

WIPO Re:Search

WIPO Re:Search is an R&D consortium dedicated to developing new solutions—including medicines, vaccines and diagnostics—for neglected tropical diseases, malaria and tuberculosis. The consortium was created in partnership with the World Intellectual Property Organization (WIPO), BIO Ventures for Global Health and other leaders in the R&D pharmaceutical industry.

ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established by Pfizer and GlaxoSmithKline in 2009 to deliver advances in treatment and care for people living with HIV. Shionogi joined ViiV Healthcare in 2012. ViiV Healthcare aims to take a deeper and broader interest in HIV/AIDS than any company has done before, while taking a new approach to deliver effective and new HIV medicines, as well as to support communities affected by HIV.

INFRASTRUCTURE AND CAPACITY

Building Health Care Infrastructure and Capacity Worldwide

Pfizer helps build health care infrastructure and capacity primarily in two ways:

1. By working in partnership with non-government organizations, government agencies, multilateral aid organizations and other global health stakeholders to strengthen health care systems and improve care.

2. Through product donation and patient assistance programs that improve access to our medicines.

A synopsis of our social investment programs may be found here.

These investments include programs that provide direct assistance, such as product donations and steep discounts, to help bridge current gaps in health care delivery to various underserved populations. For example, we donate Zithromax to fight blinding trachoma and Diflucan to fight opportunistic fungal infections associated with HIV and AIDS in the developing world. Pfizer Helpful Answers helps eligible patients in the U.S. with their Pfizer prescriptions for free or at a savings and, in some cases, offers reimbursement support services.
Spotlight on Vaccines

We are doing our part to help lessen the societal burden of preventable disease.

EXPANDING ACCESS TO VACCINES

Today, more people benefit from safe and efficacious vaccines than ever before. As Pfizer works to usher in a new era of vaccine innovation—both to prevent and treat disease—we are also working with governments and global health organizations to expand access to these treatments.

National Immunization Programs

We seek to make accessible our potentially life-saving vaccines through national immunization programs (NIPs), an important channel that provides an organized system of vaccine procurement and utilization for countries and agencies around the world. The overarching goal of such programs is to ensure proper delivery and utilization of vaccines in a cost-effective and efficient manner. Over many years, Pfizer has successfully collaborated with more than 60 governments in developed, developing and emerging markets worldwide to establish or maintain pneumococcal disease prevention programs that help to protect nearly 30 million children.

Bringing Prevenar 13 to Children in Need

We are committed to helping protect millions of infants and young children in the developing world from pneumococcal disease, the leading cause of vaccine-preventable death in young children. Under the auspices of the GAVI Alliance’s Advance Market Commitment (AMC) for pneumococcal vaccines, Pfizer will supply up to 480 million doses of Prevenar 13 through 2023. Within only two years of the launch of the AMC, Prevenar 13 is available in 20 GAVI-eligible countries, with many additional launches planned.
Pfizer’s Investments in Health

Our social investments focus on effective and sustainable health care delivery for underserved patients while empowering our colleagues, strengthening our stakeholder relationships, and ultimately having a positive impact on society and our business.

For an interactive map of all our access-related programs, see here.

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>DESCRIPTION</th>
<th>TARGET REGION</th>
<th>IMPACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Helpful Answers</td>
<td>Provide Pfizer medicines for free or at a savings to patients who qualify.</td>
<td>U.S.</td>
<td>Enabled more than 3.4 million uninsured or underinsured patients to get access to nearly 39.2 million Pfizer prescriptions from 2008 to 2012.</td>
</tr>
<tr>
<td>Infectious Disease Institute</td>
<td>Build capacity for prevention, treatment, training, and clinical services in Uganda.</td>
<td>Africa</td>
<td>Provide ongoing care and treatment to more than 36,500 patients, with outreach to 688,000 individuals; more than 10,300 health care workers from 28 countries received training in HIV/AIDS since program inception.</td>
</tr>
<tr>
<td>Global Health Fellows</td>
<td>Improve access, quality, and efficiency of health services for underserved populations through individual three to six month assignments and two to three week team volunteer assignments.</td>
<td>Global—Africa, Asia, Latin America, Europe, U.S.</td>
<td>Since 2003, 377 colleagues have completed an estimated 334,000 hours of skills-based volunteering, which is valued at approximately $49 million of pro bono service to partner organizations throughout the world. Through GHF, Pfizer has partnered with more than 40 international development organizations in more than 40 countries. 2013 marks the 10th anniversary of the program.</td>
</tr>
<tr>
<td>International Trachoma Initiative</td>
<td>Goal to eliminate trachoma by 2020 through the donation of Zithromax and an integrated public health strategy.</td>
<td>Africa, Asia, Latin America</td>
<td>Pfizer has shipped more than 340 million Zithromax treatments to date.</td>
</tr>
<tr>
<td>Mobilize Against Malaria</td>
<td>Educate treatment providers and patients to improve malaria treatment.</td>
<td>Ghana, Kenya, Senegal</td>
<td>Over 1,200 Licensed Chemical Sellers trained to correctly dose and administer ACTs, and to recognize and refer complicated malaria cases in Ghana. Over 1,600 staff trained to advise women on prevention and treatment of malaria in Kenya. Over 200 community health workers and nurses trained in malaria diagnosis and treatment at 24 health huts in Senegal.</td>
</tr>
<tr>
<td>Global Health Partnership</td>
<td>Strengthen innovative public health partnerships that address challenges in cancer and tobacco control, in support of the noncommunicable diseases movement.</td>
<td>47 countries in Asia, Latin America, Europe, Africa, North America</td>
<td>More than 97,000 patients served and 266,000 health care workers trained from 2008 to 2011.</td>
</tr>
<tr>
<td>Diflucan Partnership Program</td>
<td>Donate Diflucan for the treatment of two opportunistic infections associated with HIV and AIDS: cryptococcal meningitis and esophageal candidiasis.</td>
<td>63 countries in Africa, Asia, Latin America</td>
<td>Over a 12-year period, the program has provided over $1.3 billion in medicine to more than 2,600 sites in 63 countries.</td>
</tr>
</tbody>
</table>
GREATER IMPACT

PATIENT SAFETY

Innovations in Patient Care and Safety

As a leader in biopharmaceutical research, we have great interest in new tools that help physicians and other health care professionals improve patient care and ensure patient safety, including mobile health platforms. Our collaboration with Epocrates—the leading mHealth software provider, used by more than 1 million physicians in the U.S.—improves real-time decision-making by providing health care professionals with detailed, up-to-date clinical information on Pfizer products, as well as one-click access to doctors working with Pfizer. In addition, Pfizer remains the only major biopharmaceutical company whose website expedites a direct link for patients to file adverse event reports with the FDA.

OUR FIRST PRIORITY

“Patient safety is a core value and our absolute first priority—from the moment a compound is cleared for clinical trials, to its approval by regulators for use by patients, through its manufacture and distribution, and for as long as it is for sale and in use anywhere in the world.”

Freda Lewis-Hall, M.D.
Chief Medical Officer

OWNING TRUST

WATCH DR. FREDA LEWIS-HALL DISCUSS MIGRAINE ON THE DOCTORS

WATCH DR. FREDA LEWIS-HALL DISCUSS ARTHRITIS ON THE DOCTORS
Communicating Safety Information

We empower patients, their caregivers and the public with up-to-date, meaningful information—clearly explaining the benefits, risks and proper use of our medicines—to drive the best possible patient outcomes.

Pfizer’s External Medical Communications team has hundreds of medical professionals standing ready to discuss with doctors and other licensed prescribers how our medicines are properly prescribed, and to answer questions about their risk and benefit profiles. PfizerPro.com and PfizerMedicalInformation.com, both available exclusively to prescribers, provide extensive information on Pfizer medicines and an array of patient support resources, including patient assistance programs.

The Pfizer Medicine Safety Education website shows how a medicine’s safety profile is determined, monitored and communicated. It includes a direct link to MedWatch, the U.S. FDA’s Safety Information and Adverse Event reporting program.

Protecting Patients from Counterfeit and Substandard Medicines

Counterfeit medicines are relatively easy to make and pose a serious public health risk. Pfizer has taken a leadership position among pharmaceutical companies to protect patients, working in close coordination with many national authorities and multinational coalitions to fight the counterfeiting of medicines. Our partnerships with enforcement authorities are key to our progress.

We are also experimenting with direct-to-consumer models that reduce the possibility of counterfeit medicines entering legitimate supply channels, including pilot programs to give patients a trusted online alternative source for medicines such as Viagra, the most counterfeited medicine in the world.

+800,000
Prescriber Inquiries Answered per Year

+100,000
Unique Visitors to Our Medicine Safety Education website

160 MILLION
Counterfeit Doses of Pfizer Medicines Seized Since 2004

1 IN 2
Odds of Receiving a Counterfeit Medicine When Ordering from a “Rogue” Pharmacy—One Concealing Its True Location

106 COUNTRIES
Countries Where Counterfeit Pfizer Drugs Have Been Found

$0 COST
Cost to Authorities to Test Suspected Pfizer Products
GREATER IMPACT

ENVIRONMENT

Committed to a Sustainable Future

To all of us at Pfizer, the commitment to advancing health includes being good stewards of the environment.

PFIZER’S GREEN JOURNEY

Our “green journey” program focuses on three areas key to our business: helping to mitigate climate change and its impacts; minimizing the environmental impact of our products and processes by advancing stewardship across the supply chains and life cycles of our products; and managing water resources in a sustainable way. We take an entrepreneurial approach to sustainability practices that produce measurable value for our business and society in reducing reliance on energy and water and looking for innovative ways to better manage waste.

For a comprehensive view of our contributions to a sustainable future, see here.

20%
Met a second, five-year public goal of reducing greenhouse gas emissions by 20% after only four years.

25%
Obtained 25% of our Electricity from Solar, Wind, Hydro and Cogeneration.

Achieved outstanding sustainability ratings in the health care sector from influential groups: #1 Bloomberg Maplecroft, #6 Newsweek, #3 CDP Performance, #10 CDP Disclosure.

Celebrated a decade of Green Chemistry leadership, recognizing significant solvent and waste reductions, safer chemistry methods and greener processes.

Issued guides for colleagues to adopt greener practices in travel, printing, and energy savings.

Mapped locations for operations in water scarce areas, including top suppliers.

Participated in creating industry carbon footprint guide for the National Health Service.
Pharmaceuticals in the Environment

Pfizer has an active program to assess and address the issues associated with pharmaceuticals in the environment. We help to educate patients on the proper disposal of medicines, and we participate in product take-back programs in locations that operate them. To aid U.S. hospitals and health care clinics on responsible disposal of unused medicines, Pfizer, in collaboration with Waste Management, introduced an online guide listing disposal information for our products—a first in the industry.

For more on our approach to pharmaceuticals in the environment, see here or go directly to Pfizer’s Position Statement on the topic and to the Pfizer Responsible Disposal Advisor.

Managing Environmental Risk

People at all levels of our company are involved with managing environmental risk and liabilities, beginning with oversight by the Audit Committee of the Board of Directors, governance by our Environmental Sustainability Council, and execution through teams at each of our major sites.

For more information on our environment, health and safety program, including compliance and environmental remediation, please see www.pfizer.com/ehs.
## GRI INDEX

### 1. Strategy and Analysis

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Statement from the most senior decision-maker of the organization (e.g., CEO, chair, or equivalent senior position) about the relevance of sustainability to the organization and its strategy.</td>
<td>From Our CEO</td>
<td></td>
</tr>
<tr>
<td>1.2 Description of key impacts, risks, and opportunities.</td>
<td>From Our CEO</td>
<td>8</td>
</tr>
</tbody>
</table>

- Covered  ● Partially Covered  ● Not Covered

### 2. Organizational Profile

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Name of the organization.</td>
<td>Corporate Overview</td>
<td></td>
</tr>
<tr>
<td>2.2 Primary brands, products, and/or services.</td>
<td>Pfizer Products</td>
<td></td>
</tr>
<tr>
<td>2.3 Operational structure of the organization, including main divisions, operating companies, subsidiaries, and joint ventures.</td>
<td>How We Are Organized</td>
<td></td>
</tr>
<tr>
<td>2.4 Location of organization’s headquarters.</td>
<td>Contact</td>
<td></td>
</tr>
<tr>
<td>2.5 Number of countries where the organization operates, and names of countries with either major operations or that are specifically relevant to the sustainability issues covered in the report.</td>
<td>Global Sites</td>
<td></td>
</tr>
<tr>
<td>2.6 Nature of ownership and legal form.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.7 Markets served (including geographic breakdown, sectors served, and types of customers/beneficiaries).</td>
<td>About This Review</td>
<td></td>
</tr>
<tr>
<td>2.8 Scale of the reporting organization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.9 Significant changes during the reporting period regarding size, structure, or ownership.</td>
<td>About This Review</td>
<td></td>
</tr>
<tr>
<td>2.10 Awards received in the reporting period.</td>
<td>Accolades</td>
<td></td>
</tr>
</tbody>
</table>

- Covered  ● Partially Covered  ● Not Covered
### 3. Report Parameters

#### REPORT PROFILE

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Reporting period (e.g., fiscal/calendar year) for information provided.</td>
<td>About This Review</td>
<td></td>
</tr>
<tr>
<td>3.2 Date of most recent previous report (if any).</td>
<td>Financial Reports</td>
<td></td>
</tr>
<tr>
<td>3.3 Reporting cycle (annual, biennial, etc.)</td>
<td>About This Review</td>
<td></td>
</tr>
<tr>
<td>3.4 Contact point for questions regarding the report or its contents.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### REPORT SCOPE AND BOUNDARY

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.5 Process for defining report content.</td>
<td>About This Review</td>
<td></td>
</tr>
<tr>
<td>3.6 Boundary of the report (e.g., countries, divisions, subsidiaries, leased facilities, joint ventures, suppliers). See GRI Boundary Protocol for further guidance.</td>
<td>About This Review</td>
<td></td>
</tr>
<tr>
<td>3.7 State any specific limitations on the scope or boundary of the report.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.8 Basis for reporting on joint ventures, subsidiaries, leased facilities, outsourced operations, and other entities that can significantly affect comparability from period to period and/or between organizations.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.9 Data measurement techniques and the bases of calculations, including assumptions and techniques underlying estimations applied to the compilation of the Indicators and other information in the report.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.10 Explanation of the effect of any re-statements of information provided in earlier reports, and the reasons for such re-statement (e.g., mergers/acquisitions, change of base years/periods, nature of business, measurement methods).</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>3.11 Significant changes from previous reporting periods in the scope, boundary, or measurement methods applied in the report.</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

#### GRI CONTENT INDEX

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.12 Table identifying the location of the Standard Disclosures in the report.</td>
<td>GRI Index</td>
<td></td>
</tr>
</tbody>
</table>

#### ASSURANCE

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.13 Policy and current practice with regard to seeking external assurance for the report. If not included in the assurance report accompanying the sustainability report, explain the scope and basis of any external assurance provided. Also explain the relationship between the reporting organization and the assurance provider(s).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Covered*  | *Partially Covered*  | *Not Covered*
4. Governance, Commitments, and Engagement

**GOVERNANCE**

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 Governance structure of the organization, including committees under the highest governance body responsible for specific tasks, such as setting strategy or organizational oversight.</td>
<td>Corporate Governance</td>
<td></td>
</tr>
<tr>
<td>4.2 Indicate whether the Chair of the highest governance body is also an executive officer (and, if so, their function within the organization’s management and the reasons for this arrangement).</td>
<td>Pfizer Executive Leadership Team</td>
<td></td>
</tr>
<tr>
<td>4.3 For organizations that have a unitary board structure, state the number of members of the highest governance body that are independent and/or non-executive members.</td>
<td>Fact Sheet</td>
<td></td>
</tr>
<tr>
<td>4.4 Mechanisms for shareholders and employees to provide recommendations or direction to the highest governance body.</td>
<td>Contact Directors</td>
<td></td>
</tr>
<tr>
<td>4.5 Linkage between compensation for members of the highest governance body, senior managers, and executives (including departure arrangements), and the organization’s performance (including social and environmental performance).</td>
<td>Compensation</td>
<td></td>
</tr>
<tr>
<td>4.6 Processes in place for the highest governance body to ensure conflicts of interest are avoided.</td>
<td>Director Code of Conduct</td>
<td></td>
</tr>
<tr>
<td>4.7 Process for determining the qualifications and expertise of the members of the highest governance body for guiding the organization’s strategy on economic, environmental, and social topics.</td>
<td>Corporate Governance</td>
<td></td>
</tr>
<tr>
<td>4.8 Internally developed statements of mission or values, codes of conduct, and principles relevant to economic, environmental, and social performance and the status of their implementation.</td>
<td>Compliance</td>
<td></td>
</tr>
<tr>
<td>4.9 Procedures of the highest governance body for overseeing the organization’s identification and management of economic, environmental, and social performance, including relevant risks and opportunities, and adherence or compliance with internationally agreed standards, codes of conduct, and principles.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.10 Processes for evaluating the highest governance body’s own performance, particularly with respect to economic, environmental, and social performance.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## COMMISSIONENTS TO EXTERNAL INITIATIVES

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.11 Explanation of whether and how the precautionary approach or principle is addressed by the organization.</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>4.12 Externally developed economic, environmental, and social charters, principles, or other initiatives to which the organization subscribes or endorses.</td>
<td>Sales and Marketing Expanding Access to Health Manufacturing and Supply Chain</td>
<td></td>
</tr>
<tr>
<td>4.13 Memberships in associations (such as industry associations) and/or national/international advocacy organizations in which the organization: - has positions in governance bodies; - participates in projects or committees; - provides substantive funding beyond routine membership dues; - views membership as strategic.</td>
<td>Trade Association Memberships</td>
<td></td>
</tr>
</tbody>
</table>

## STAKEHOLDER ENGAGEMENT

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.14 List of stakeholder groups engaged by the organization.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.15 Basis for identification and selection of stakeholders with whom to engage.</td>
<td>Expanding Access to Health</td>
<td></td>
</tr>
<tr>
<td>4.16 Approaches to stakeholder engagement, including frequency of engagement by type and by stakeholder group.</td>
<td>Expanding Access to Health</td>
<td></td>
</tr>
<tr>
<td>4.17 Key topics and concerns that have been raised through stakeholder engagement, and how the organization has responded to those key topics and concerns, including through its reporting.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Covered**
- **Partially Covered**
- **Not Covered**
5. Management Approach and Performance Indicators

ECONOMIC DISCLOSURES
The economic dimension of sustainability concerns the organization’s impacts on the economic conditions of its stakeholders and on economic systems at local, national, and global levels. The Economic Indicators illustrate:

- Flow of capital among different stakeholders; and
- Main economic impacts of the organization throughout society.

Financial performance is fundamental to understanding an organization and its own sustainability. However, this information is normally already reported in financial accounts. What is often reported less, and is frequently desired by users of sustainability reports, is the organization’s contribution to the sustainability of a larger economic system.

DISCLOSURE ON MANAGEMENT APPROACH (ECONOMY)
Provide a concise disclosure on the Management Approach items outlined below with reference to the following Economic Aspects:

- Economic Performance;
- Market Presence; and
- Indirect Economic Impacts.

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
</table>
| GOALS AND PERFORMANCE | From Our CEO | Financial Performance  
Global Opportunities  
Expanding Access to Health |
| Organization-wide goals regarding performance relevant to the Economic Aspects. Use organization-specific Indicators (as needed) in addition to the GRI Performance Indicators to demonstrate the results of performance against goals. | | |
| POLICY | From Our CEO  
Financial Performance  
Global Opportunities  
Expanding Access to Health | |
| Brief, organization-wide policy (or policies) that defines the organization’s overall commitment relating to the Economic Aspects listed above, or state where this can be found in the public domain (e.g., web link). | | |
| ADDITIONAL CONTEXTUAL INFORMATION | From Our CEO  
Financial Performance  
Global Opportunities  
Expanding Access to Health | |
| Additional relevant information required to understand organizational performance, such as: | | |
| - Key successes and shortcomings;  
- Major organizational risks and opportunities;  
- Major changes in the reporting period to systems or structures to improve performance; and  
- Key strategies for implementing policies or achieving performance. | | |
### ECONOMIC PERFORMANCE INDICATORS

#### ASPECT: ECONOMIC PERFORMANCE

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC1</td>
<td>Direct economic value generated and distributed, including revenues, operating costs, employee compensation, donations and other community investments, retained earnings, and payments to capital providers and governments.</td>
<td>Financial Performance</td>
</tr>
<tr>
<td>EC2</td>
<td>Financial implications and other risks and opportunities for the organization’s activities due to climate change.</td>
<td>Climate Change, Position Statement</td>
</tr>
<tr>
<td>EC3</td>
<td>Coverage of the organization’s defined benefit plan obligations.</td>
<td></td>
</tr>
<tr>
<td>EC4</td>
<td>Significant financial assistance received from government.</td>
<td></td>
</tr>
</tbody>
</table>

#### ASPECT: MARKET PRESENCE

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC5</td>
<td>Range of ratios of standard entry level wage compared to local minimum wage at significant locations of operation.</td>
<td></td>
</tr>
<tr>
<td>EC6</td>
<td>Policy, practices, and proportion of spending on locally-based suppliers at significant locations of operation.</td>
<td></td>
</tr>
<tr>
<td>EC7</td>
<td>Procedures for local hiring and proportion of senior management hired from the local community at locations of significant operation.</td>
<td></td>
</tr>
</tbody>
</table>

#### ASPECT: INDIRECT ECONOMIC IMPACTS

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC8</td>
<td>Development and impact of infrastructure investments and services provided primarily for public benefit through commercial, in-kind, or pro bono engagement.</td>
<td>Expanding Access to Health</td>
</tr>
<tr>
<td>EC9</td>
<td>Understanding and describing significant indirect economic impacts, including the extent of impacts.</td>
<td>Expanding Access to Health</td>
</tr>
</tbody>
</table>
ENVIRONMENTAL DISCLOSURES
The environmental dimension of sustainability concerns an organization’s impacts on living and non-living natural systems, including ecosystems, land, air, and water. Environmental Indicators cover performance related to inputs (e.g., material, energy, water) and outputs (e.g., emissions, effluents, waste). In addition, they cover performance related to biodiversity, environmental compliance, and other relevant information such as environmental expenditure and the impacts of products and services.

DISCLOSURE ON MANAGEMENT APPROACH (ENVIRONMENT)
Provide a concise disclosure on the Management Approach items outlined below with reference to the following Environmental Aspects:

- Materials;
- Energy;
- Water;
- Biodiversity;
- Emissions, Effluents, and Waste;
- Products and Services;
- Compliance;
- Transport; and
- Overall

GOALS AND PERFORMANCE
Organization-wide goals regarding performance relevant to the Environment Aspects.
Use organization-specific Indicators (as needed) in addition to the GRI Performance Indicators to demonstrate the results of performance against goals.

POLICY
Brief, organization-wide policy (or policies) that defines the organization’s overall commitment related to the Environmental Aspects listed above or state where this can be found in the public domain (e.g., web link).

ORGANIZATIONAL RESPONSIBILITY
The most senior position with operational responsibility for Environmental Aspects or explain how operational responsibility is divided at the senior level for these Aspects. This differs from Disclosure 4.1, which focuses on structures at the governance level.

TRAINING AND AWARENESS
Procedures related to training and raising awareness in relation to the Environmental Aspects.

MONITORING AND FOLLOW-UP
Procedures related to monitoring and corrective and preventive actions, including those related to the supply chain.
List of certifications for environment-related performance or certification systems, or other approaches to auditing/verification for the reporting organization or its supply chain.

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOALS AND PERFORMANCE</td>
<td>Protecting the Environment</td>
<td></td>
</tr>
<tr>
<td>POLICY</td>
<td>EHS Policy Statement</td>
<td></td>
</tr>
<tr>
<td>ORGANIZATIONAL RESPONSIBILITY</td>
<td>EHS Governance</td>
<td></td>
</tr>
<tr>
<td>TRAINING AND AWARENESS</td>
<td>Supplier Review</td>
<td></td>
</tr>
<tr>
<td>MONITORING AND FOLLOW-UP</td>
<td>Key Performance Indicators</td>
<td></td>
</tr>
</tbody>
</table>
**ADDITIONAL CONTEXTUAL INFORMATION**

Additional relevant information required to understand organizational performance, such as:

- Key successes and shortcomings;
- Major organizational risks and opportunities;
- Major changes in the reporting period to systems or structures to improve performance; and
- Key strategies and procedures for implementing policies or achieving goals.

**ENVIRONMENTAL PERFORMANCE INDICATORS**

**ASPECT: MATERIALS**

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN1 Materials used by weight or volume.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN2 Percentage of materials used that are recycled input materials.</td>
<td></td>
<td>8, 9</td>
</tr>
</tbody>
</table>

**ASPECT: ENERGY**

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN3 Direct energy consumption by primary energy source.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN4 Indirect energy consumption by primary source.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN5 Energy saved due to conservation and efficiency improvements.</td>
<td></td>
<td>8, 9</td>
</tr>
<tr>
<td>EN6 Initiatives to provide energy-efficient or renewable energy based products and services, and reductions in energy requirements as a result of these initiatives.</td>
<td></td>
<td>8, 9</td>
</tr>
<tr>
<td>EN7 Initiatives to reduce indirect energy consumption and reductions achieved.</td>
<td></td>
<td>8, 9</td>
</tr>
</tbody>
</table>

**ASPECT: WATER**

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN8 Total water withdrawal by source.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN9 Water sources significantly affected by withdrawal of water.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN10 Percentage and total volume of water recycled and reused.</td>
<td></td>
<td>8</td>
</tr>
</tbody>
</table>
### ASPECT: BIODIVERSITY

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN11 Location and size of land owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN12 Description of significant impacts of activities, products, and services on biodiversity in protected areas and areas of high biodiversity value outside protected areas.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN13 Habitats protected or restored.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN14 Strategies, current actions, and future plans for managing impacts on biodiversity.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN15 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction risk.</td>
<td></td>
<td>8</td>
</tr>
</tbody>
</table>

### ASPECT: EMISSIONS, EFFLUENTS, AND WASTE

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN16 Total direct and indirect greenhouse gas emissions by weight.</td>
<td>Environment KPIs</td>
<td>8</td>
</tr>
<tr>
<td>EN17 Other relevant indirect greenhouse gas emissions by weight.</td>
<td>EHS Performance Dashboard</td>
<td>8, 9</td>
</tr>
<tr>
<td>EN18 Initiatives to reduce greenhouse gas emissions and reductions achieved.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN19 Emissions of ozone-depleting substances by weight.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN20 NO, SO, and other significant air emissions by type and weight.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN21 Total water discharge by quality and destination.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN22 Total weight of waste by type and disposal method.</td>
<td>EHS Performance Dashboard</td>
<td>8</td>
</tr>
<tr>
<td>EN23 Total number and volume of significant spills.</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>EN24 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally.</td>
<td>EHS Performance Dashboard</td>
<td>8</td>
</tr>
<tr>
<td>EN25 Identity, size, protected status, and biodiversity value of water bodies and related habitats significantly affected by the reporting organization’s discharges of water and runoff.</td>
<td></td>
<td>8</td>
</tr>
</tbody>
</table>

### ASPECT: PRODUCTS AND SERVICES

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN26 Initiatives to mitigate environmental impacts of products and services, and extent of impact mitigation.</td>
<td>Green Journey</td>
<td>8, 9</td>
</tr>
<tr>
<td>EN27 Percentage of products sold and their packaging materials that are reclaimed by category.</td>
<td></td>
<td>8, 9</td>
</tr>
</tbody>
</table>
ASPECT: COMPLIANCE

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN28 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations.</td>
<td>EHS Compliance</td>
<td>8</td>
</tr>
</tbody>
</table>

ASPECT: TRANSPORT

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN29 Significant environmental impacts of transporting products and other goods and materials used for the organization’s operations, and transporting members of the workforce.</td>
<td></td>
<td>8</td>
</tr>
</tbody>
</table>

ASPECT: OVERALL

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EN30 Total environmental protection expenditures and investments by type.</td>
<td></td>
<td>8</td>
</tr>
</tbody>
</table>

SOCIAL DISCLOSURES

The social dimension of sustainability concerns the impacts an organization has on the social systems within which it operates. The GRI Social Performance Indicators identify key Performance Aspects surrounding labor practices, human rights, society, and product responsibility.

LABOR PRACTICES AND DECENT WORK

The specific Aspects under the category of Labor Practices are based on internationally recognized universal standards, including:

- United Nations Convention: International Covenant on Civil and Political Rights;
- ILO Declaration on Fundamental Principles and Rights at Work of 1998 (in particular the eight core conventions of the ILO); and
- The Vienna Declaration and Programme of Action.
### DISCLOSURE ON MANAGEMENT APPROACH (LABOR PRACTICES AND DECENT WORK)

Provide a concise disclosure on the following Management Approach items with reference to the Labor Aspects listed below. The ILO Tripartite Declaration Concerning Multinational Enterprises and Social Policy (in particular the eight core conventions of the ILO) and the Organisation for Economic Co-operation and Development Guidelines for Multinational Enterprises, should be the primary reference points.

- Employment;
- Labor/Management Relations;
- Occupational Health and Safety;
- Training and Education; and
- Diversity and Equal Opportunity.

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GOALS AND PERFORMANCE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organization-wide goals regarding performance relevant to the Labor Aspects, indicating their linkage to the internationally recognized universal standards. Use organization-specific Indicators (as needed) in addition to the GRI Performance Indicators to demonstrate the results of performance against goals.</td>
<td>Human Rights</td>
<td></td>
</tr>
<tr>
<td><strong>POLICY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brief, organization-wide policy (or policies) that defines the organization’s overall commitment related to the Labor Aspects, or state where this can be found in the public domain (e.g., web link). Also reference their linkage to the international standards indicated above.</td>
<td>Human Rights Compliance</td>
<td></td>
</tr>
<tr>
<td><strong>ORGANIZATIONAL RESPONSIBILITY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The most senior position with operational responsibility for Labor Aspects or explain how operational responsibility is divided at the senior level for these Aspects. This differs from Disclosure 4.1, which focuses on structures at the governance level.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TRAINING AND AWARENESS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedures related to training and raising awareness in relation to the Labor Aspects.</td>
<td>Compliance</td>
<td></td>
</tr>
<tr>
<td><strong>MONITORING AND FOLLOW-UP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedures related to monitoring and corrective and preventive actions, including those related to the supply chain.</td>
<td>PSCI and External Certifications EHS External Supply Compliance</td>
<td></td>
</tr>
<tr>
<td>List of certifications for labor-related performance or certification systems, or other approaches to auditing/verifying the reporting organization or its supply chain.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ADDITIONAL CONTEXTUAL INFORMATION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional relevant information required to understand organizational performance, such as:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Key successes and shortcomings;</td>
<td>Human Rights</td>
<td></td>
</tr>
<tr>
<td>- Major organizational environmental risks and opportunities related to issues;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Major changes in the reporting period to systems or structures to improve performance; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Key strategies and procedures for implementing policies or achieving goals</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### LABOR PRACTICES AND DECENT WORK PERFORMANCE INDICATORS

#### ASPECT: EMPLOYMENT

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>LA1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA2</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>LA3</td>
<td></td>
<td>6</td>
</tr>
</tbody>
</table>

#### ASPECT: LABOR/MANAGEMENT RELATIONS

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>LA4</td>
<td></td>
<td>1, 3</td>
</tr>
<tr>
<td>LA5</td>
<td></td>
<td>3</td>
</tr>
</tbody>
</table>

#### ASPECT: OCCUPATIONAL HEALTH AND SAFETY

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>LA6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA7</td>
<td>EHS Performance Dashboard</td>
<td></td>
</tr>
<tr>
<td>LA8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA9</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### ASPECT: TRAINING AND EDUCATION

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>LA10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA12</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ASPECT: DIVERSITY AND EQUAL OPPORTUNITY

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>LA13 Composition of governance bodies and breakdown of employees per category according to gender, age group, minority group membership, and other indicators of diversity.</td>
<td>●</td>
<td>1, 6</td>
</tr>
<tr>
<td>LA14 Ratio of basic salary of men to women by employee category.</td>
<td>●</td>
<td>1, 6</td>
</tr>
</tbody>
</table>

HUMAN RIGHTS

Human Rights Performance Indicators require organizations to report on the extent to which human rights are considered in investment and supplier/contractor selection practices. Additionally, the Indicators cover employee and security forces training on human rights as well as non-discrimination, freedom of association, child labor, indigenous rights, and forced and compulsory labor.

Generally recognized human rights are defined by the following Conventions and Declarations:

- United Nations Convention: International Covenant on Civil and Political Rights;
- ILO Declaration on Fundamental Principles and Rights at Work of 1998 (in particular the eight core conventions of the ILO); and
- The Vienna Declaration and Programme of Action.

DISCLOSURE ON MANAGEMENT APPROACH (HUMAN RIGHTS)

Provide a concise disclosure on the following Management Approach items with reference to the Human Rights Aspects listed below. The ILO Tripartite Declaration Concerning Multinational Enterprises and Social Policy (in particular the eight core conventions of the ILO which consist of Conventions 100, 111, 87, 98, 138, 182, 20 and 1059), and the Organisation for Economic Cooperation and Development Guidelines for Multinational Enterprises should be the primary reference points.

- Investment and Procurement Practices;
- Non-discrimination;
- Freedom of Association and Collective Bargaining;
- Abolition of Child Labor;
- Prevention of Forced and Compulsory Labor;
- Complaints and Grievance Practices;
- Security Practices; and
- Indigenous Rights.
<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOALS AND PERFORMANCE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organization-wide goals regarding performance relevant to the Human Rights Aspects, indicating their linkage to the international declarations and standards listed above. Use organization-specific Indicators (as needed) in addition to the GRI Performance Indicators to demonstrate the results of performance against goals.</td>
<td>Human Rights</td>
<td></td>
</tr>
<tr>
<td>POLICY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brief, organization-wide policy (or policies) that defines the organization’s overall commitment to the Human Rights Aspects (including policies which may be reasonably considered likely to affect the decision of employees to join a trade union or bargain collectively), or state where this can be found in the public domain (e.g., web link). Also reference their linkage to the international declarations and standards indicated above.</td>
<td>Human Rights</td>
<td></td>
</tr>
<tr>
<td>ORGANIZATIONAL RESPONSIBILITY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The most senior position with operational responsibility for Human Rights Aspects or explain how operational responsibility is divided at the senior level for these Aspects. This differs from Disclosure 4.1, which focuses on structures at the governance level.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRAINING AND AWARENESS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedures related to training and raising awareness in relation to the Human Rights Aspects.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MONITORING AND FOLLOW-UP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedures related to monitoring and corrective and preventive actions, including those related to the supply chain. List of certifications for human rights-related performance, or certification systems, or other approaches to auditing/verifying the reporting organization or its supply chain.</td>
<td>PSCI and External Certifications EHS External Supply Corporate Compliance</td>
<td></td>
</tr>
<tr>
<td>ADDITIONAL CONTEXTUAL INFORMATION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional relevant information required to understand organizational performance, such as:</td>
<td>Human Rights</td>
<td></td>
</tr>
<tr>
<td>• Key successes and shortcomings;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Major organizational risks and opportunities;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Major changes in the reporting period to systems or structures to improve performance; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Key strategies and procedures for implementing policies or achieving goals.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### HUMAN RIGHTS PERFORMANCE INDICATORS

**ASPECT: INVESTMENT AND PROCUREMENT PRACTICES**

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR1 Percentage and total number of significant investment agreements that include human rights clauses or that have undergone human rights screening.</td>
<td>✔</td>
<td>1, 2, 3, 4, 5, 6</td>
</tr>
<tr>
<td>HR2 Percentage of significant suppliers and contractors that have undergone screening on human rights and actions taken.</td>
<td>✔</td>
<td>1, 2, 3, 4, 5, 6</td>
</tr>
<tr>
<td>HR3 Total hours of employee training on policies and procedures concerning aspects of human rights that are relevant to operations, including the percentage of employees trained.</td>
<td>✔</td>
<td>1, 4, 5, 6</td>
</tr>
</tbody>
</table>

**ASPECT: NON-DISCRIMINATION**

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR4 Total number of incidents of discrimination and actions taken.</td>
<td>✔</td>
<td>1, 6</td>
</tr>
</tbody>
</table>

**ASPECT: FREEDOM OF ASSOCIATION AND COLLECTIVE BARGAINING**

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR5 Operations identified in which the right to exercise freedom of association and collective bargaining may be at significant risk, and actions taken to support these rights.</td>
<td>✔</td>
<td>1, 3</td>
</tr>
</tbody>
</table>
### ASPECT: CHILD LABOR

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR6</td>
<td></td>
<td>1, 5</td>
</tr>
<tr>
<td></td>
<td>Operations identified as having significant risk for incidents of child labor, and measures taken to contribute to the elimination of child labor.</td>
<td></td>
</tr>
</tbody>
</table>

### ASPECT: FORCED AND COMPULSORY LABOR

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR7</td>
<td></td>
<td>1, 4</td>
</tr>
<tr>
<td></td>
<td>Operations identified as having significant risk for incidents of forced or compulsory labor, and measures to contribute to the elimination of forced or compulsory labor.</td>
<td></td>
</tr>
</tbody>
</table>

### ASPECT: SECURITY PRACTICES

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR8</td>
<td></td>
<td>1, 2</td>
</tr>
<tr>
<td></td>
<td>Percentage of security personnel trained in the organization’s policies or procedures concerning aspects of human rights that are relevant to operations.</td>
<td></td>
</tr>
</tbody>
</table>

### ASPECT: INDIGENOUS RIGHTS

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR9</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Total number of incidents of violations involving rights of indigenous people and actions taken.</td>
<td></td>
</tr>
</tbody>
</table>
SOCIETY
Society Performance Indicators focus attention on the impacts organizations have on the communities in which they operate, and disclosing how the risks that may arise from interactions with other social institutions are managed and mediated. In particular, information is sought on the risks associated with bribery and corruption, undue impudence in public policy-making, and monopoly practices.

DISCLOSURE ON MANAGEMENT APPROACH (SOCIETY)
Provide a concise disclosure on the following Management Approach items with reference to the Society Aspects:

- Community;
- Corruption;
- Public Policy;
- Anti-Competitive Behavior; and
- Compliance.

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOALS AND PERFORMANCE</td>
<td>• Compliance</td>
<td></td>
</tr>
<tr>
<td>Organization-wide goals regarding performance relevant to the Aspects indicated above. Use organization-specific Indicators as needed in addition to the GRI Performance Indicators to demonstrate the results of performance against goals.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POLICY</td>
<td>• Compliance</td>
<td></td>
</tr>
<tr>
<td>Brief, organization-wide policy (or policies) that defines the organization’s overall commitment relating to the Society Aspects or state where this can be found in the public domain (e.g., web link).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORGANIZATIONAL RESPONSIBILITY</td>
<td>• Compliance</td>
<td></td>
</tr>
<tr>
<td>The most senior position with operational responsibility for Society Aspects or explain how operational responsibility is divided at the senior level for these Aspects. This differs from Disclosure 4.1, which focuses on structures at the governance level.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRAINING AND AWARENESS</td>
<td>• Compliance</td>
<td></td>
</tr>
<tr>
<td>Procedures related to training and raising awareness in relation to the Society Aspects.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MONITORING AND FOLLOW-UP</td>
<td>• Compliance</td>
<td></td>
</tr>
<tr>
<td>Procedures related to monitoring and corrective and preventive actions, including those related to the supply chain. List of certifications for performance or certifications systems, or other approaches to auditing/verifying the reporting organization or its supply chain.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADDITIONAL CONTEXTUAL INFORMATION</td>
<td>• Compliance</td>
<td></td>
</tr>
<tr>
<td>Additional relevant information required to understand organizational performance, such as:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Key successes and shortcomings;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Major organizational risks and opportunities;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Major changes in the reporting period to systems or structures to improve performance; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Key strategies for implementing policies or achieving performance.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### ASPECT: COMMUNITY

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>S01 Nature, scope, and effectiveness of any programs and practices that assess and manage the impacts of operations on communities, including entering, operating, and exiting.</td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

### ASPECT: CORRUPTION

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>S02 Percentage and total number of business units analyzed for risks related to corruption.</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>S03 Percentage of employees trained in organization’s anti-corruption policies and procedures.</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>S04 Actions taken in response to incidents of corruption.</td>
<td></td>
<td>10</td>
</tr>
</tbody>
</table>

### ASPECT: PUBLIC POLICY

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>S05 Public policy positions and participation in public policy development and lobbying.</td>
<td>Compliance</td>
<td>10</td>
</tr>
<tr>
<td>S06 Total value of financial and in-kind contributions to political parties, politicians, and related institutions by country.</td>
<td>Compliance</td>
<td>10</td>
</tr>
</tbody>
</table>

### ASPECT: ANTI-COMPETITIVE BEHAVIOR

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>S07 Total number of legal actions for anti-competitive behavior, anti-trust, and monopoly practices and their outcomes.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ASPECT: COMPLIANCE

<table>
<thead>
<tr>
<th>GRI GUIDELINE</th>
<th>CORRESPONDING PFIZER MATERIAL</th>
<th>UNGC PRINCIPLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>S08 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with laws and regulations.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**PRODUCT RESPONSIBILITY**

Product Responsibility Performance Indicators address the aspects of a reporting organization’s products and services that directly abet customers, namely, health and safety, information and labeling, marketing, and privacy.

These aspects are chiefly covered through disclosure on internal procedures and the extent to which these procedures are not complied with.

**DISCLOSURE ON MANAGEMENT APPROACH (PRODUCT RESPONSIBILITY)**

Provide a concise disclosure on the following Management Approach items with reference to the Product Responsibility Aspects:

- Customer Health and Safety;
- Product and Service Labeling;
- Marketing Communications;
- Customer Privacy; and
- Compliance.

**GRI GUIDELINE**

**GOALS AND PERFORMANCE**

Organization-wide goals regarding performance relevant to the Product Responsibility Aspects. Use organization-specific Indicators (as needed) in addition to the GRI Performance Indicators to demonstrate the results of performance against goals.

**POLICY**

Brief, organization-wide policy (or policies) that defines the organization’s overall commitment to the Product Responsibility Aspects, or state where this can be found in the public domain (e.g., web link).

**ORGANIZATIONAL RESPONSIBILITY**

The most senior position with operational responsibility for Product Responsibility Aspects, or explain how operational responsibility is divided at the senior level for Product Responsibility Aspects. This differs from Disclosure 4.1, which focuses on structures at the governance level.

**TRAINING AND AWARENESS**

Procedures related to training and raising awareness in relation to the Product Responsibility Aspects.

**MONITORING AND FOLLOW-UP**

Procedures related to monitoring and corrective and preventive actions, including those related to the supply chain. List of certifications for product responsibility-related performance or certification systems, or other approaches to auditing/verifying the reporting organization or its supply chain.

**ADDITIONAL CONTEXTUAL INFORMATION**

Additional relevant information required to understand organizational performance, such as:

- Key successes and shortcomings;
- Major organizational risks and opportunities;
- Major changes in the reporting period to systems or structures to improve performance; and
- Key strategies for implementing policies or achieving performance.
## PRODUCT RESPONSIBILITY PERFORMANCE INDICATORS

### ASPECT: CUSTOMER HEALTH AND SAFETY

| PR1 | Life cycle stages in which health and safety impacts of products and services are assessed for improvement, and percentage of significant products and services categories subject to such procedures. | Patient Safety Research & Development Greener Process | UNGC PRINCIPLE |
| PR2 | Total number of incidents of non-compliance with regulations and voluntary codes concerning health and safety impacts of products and services during their life cycle, by type of outcomes. | | |

### ASPECT: PRODUCT AND SERVICE LABELING

| PR3 | Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirements. | Product Labeling | UNGC PRINCIPLE |
| PR4 | Total number of incidents of non-compliance with regulations and voluntary codes concerning product and service information and labeling, by type of outcomes. | | |
| PR5 | Practices related to customer satisfaction, including results of surveys measuring customer satisfaction. | | |

### ASPECT: MARKETING COMMUNICATIONS

| PR6 | Programs for adherence to laws, standards, and voluntary codes related to marketing communications, including advertising, promotion, and sponsorship. | Compliance | UNGC PRINCIPLE |
| PR7 | Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship by type of outcomes. | | |

### ASPECT: CUSTOMER PRIVACY

| PR8 | Total number of substantiated complaints regarding breaches of customer privacy and losses of customer data. | | |

### ASPECT: COMPLIANCE

| PR9 | Monetary value of significant fines for non-compliance with laws and regulations concerning the provision and use of products and services. | | |

- **Covered**
- **Partially Covered**
- **Not Covered**
CORPORATE AND SHAREHOLDER INFORMATION

STOCK LISTINGS

The principal market for our Common Stock is the New York Stock Exchange (NYSE). Our stock is also listed on the NYSE Euronext Brussels Exchange, the London Stock Exchange and the SIX Swiss Stock Exchange, as well as various United States regional stock exchanges.

STOCK TRANSFER AGENT AND REGISTRAR

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
Telephone: 1-800-PFE-9393
Outside the U.S., Canada and Puerto Rico: 1-781-575-4591
Internet: www.computershare.com

SHAREHOLDER SERVICES AND PROGRAMS

Please contact our Stock Transfer Agent and Registrar with inquiries concerning shareholder accounts of record and stock transfer matters, and also for information on the following services and programs:

- Computershare Investment Program
  - direct purchase of Pfizer stock
  - dividend reinvestment
  - automatic monthly investments
- Book-entry share ownership
- Direct deposit of dividends

FORWARD-LOOKING INFORMATION

Please refer to Pfizer’s 2012 Form 10-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this Annual Review. Our Form 10-K is available on our website at www.pfizer.com/sec and on the Securities and Exchange Commission’s website at www.sec.gov.

POLITICAL ACTION COMMITTEE (PAC)

To review our most recent PAC and corporate political contributions report, go online at www.pfizer.com/pac.

ENVIRONMENT, HEALTH AND SAFETY (EHS)

Our global EHS initiatives, Environmental Sustainability Program and performance metrics may be found online at www.pfizer.com/ehs.
HELPLINES

Patients, customers and health care professionals who have questions about any of our products should call 1-800-438-1985.

Uninsured or underinsured patients who need help getting their Pfizer medicines should call Pfizer Helpful Answers, our family of patient assistance programs that provide Pfizer medicines for free or at a savings to patients who qualify. Some programs also offer reimbursement support services for insured patients. To learn more, visit www.PfizerHelpfulAnswers.com or call 1-866-706-2400.

ADDITIONAL INFORMATION

You can find more information about Pfizer online at www.pfizer.com. Real-time news about Pfizer can be found on our Facebook page (www.facebook.com/Pfizer) and through Twitter (www.Twitter.com/Pfizer_news).

This Annual Review is produced by Pfizer’s Policy, External Affairs and Communications group.

The trademarks, logos and service marks appearing in the Annual Review, whether or not appearing with the trademark symbol, are owned or licensed by Pfizer Inc or its affiliates.

Design: Ideas On Purpose, New York
Owning Collaboration Transcript:

Alberto Visintin  
One of the reasons why CTI was launched was really to accelerate the time that it takes from an idea to the bedside and this is our driving force and this is why we come to work to try to get to the bedside fast as we can with very innovative medicines. I’m Alberto Visintin and I am a project leader at Pfizer Centers for Therapeutic Innovation and my main role is to work on a team which is developing drugs to fight cancer. Doctor Dvorak’s application really stood out because of the potential that we saw right away of program was proposed to CTI.

Hal Dvorak  
Well I’m Hal Dvorak and I’ve been a pathologist, an experimental pathologist for all my career. In academia one can only go so far and obviously the goal of experimental pathology is to treat patients. In academia you simply cannot do that, you don’t have the facilities to do that you don’t have the technologies to do that and you have to have a collaboration. You have to have a collaboration with industry and Pfizer came along and CTI is just a very fine program and they have resources that I just would have no access to.

Alberto  
And we truly work in partnership and we share the goals we share responsibilities and perhaps we will share the success.

Hal  
It also helps that the people at CTI and particularly Alberto are just wonderful collaborators they’re just very smart people very intelligent people very committed people. I’m actually surprised at how committed they are to curing cancer and that’s what I want to do to.

Alberto  
We are highly motivated we have all the tools that we need. I believe this will be a success story.
Owning Potential

Transcript:

Mark Flanagan
What makes Xeljanz different is the fact that it’s a small molecule and it can be dosed orally. It’s the first in a class of compounds called JAK inhibitors and the Janus kinase program or JAK program really started at Pfizer. My name is Mark Flanagan I’m an associate research fellow at Pfizer. Once the exploratory biology was done and we had a lead molecule to work with I worked with my colleagues to synthesize approximately a thousand synthetic analogs of that original lead until we eventually found Tofacitinib which we call today Xeljanz. The molecule that we found looked very very promising. It is very gratifying to see something that we worked on in all those years of research now translated into a new treatment option for patients. We found a drug that can potentially help make them feel better that’s really an exciting moment for for us. I think that this this program is really an example of people people owning it. People working hard doing their job, working together collaboratively, so this is really a Pfizer story from beginning to end and something that the organization I think is very proud of. It’s a great feeling.
Dr. Freda Lewis-Hall
We work very hard to build and sustain trust with patients in fact we measure our success by whether or not people consider us a trusted source of information and high quality medicines. My name is Freda Lewis Hall I’m the chief medical officer at Pfizer. We have medical personnel around the world, thousands of us who are physicians and nurses and pharmacists who provide information, who help develop our clinical trials and implement them and who stand ready to answer the questions to ensure the safe effective and appropriate use of our medicines and the best possible outcome for patients. We hope to build trust with patients in three ways. The first is we want to insure their safety from the very first time one of our medicines touches them in a clinical trial to the last time any patient anywhere in the world touches one of our medicines. Second is we want to have the highest integrity of our data and the information that we are provide and then last but absolutely not least is the quality of our products. We want people to be able to trust every time they take a Pfizer medicine that it is the highest quality possible. I would absolutely recommend a Pfizer medicine to my friends and family and when they see the blue Oval they should think quality. They should think quality of the science, quality of the medicine and quality of the information that goes behind every pill.
Transcript:

Jeffrey Trocio
The Global Health Fellows program is Pfizer’s signature corporate volunteer program where they pair colleagues with different functional and technical expertise with international development organizations. My name is Jeffrey Trocio. I work at Pfizer Primary Care business unit. As a Global Health Fellow I partnered with Save Children Uganda for four months and I helped them with a five year strategy in improving maternal newborn child health in Uganda. So the impact that I have partnering with Save Children I hope will be a long lasting coalition that serves to engage regional and global actors in continuing to improve the healthcare system in Uganda. The impact that we had on different populations or clinics or hospitals was more measurable I guess, or you were able to see it much quicker because there were less layers between the work that I did and the results that were achieved. The experience makes me really proud to work at Pfizer. It’s really rewarding to be part of a team that has made an assessment, has identified needs and then has come full circle and has delivered on those needs. The Global Health Fellows program is important to Pfizer because it demonstrates leadership and commitment to it’s mission which is to improve and enhance access to healthcare around the world.
OWNING IMPACT

Transcript:

Warachal Faison
The Get Old campaign is important because it allows for a dialogue to occur. My name is Warachal Eileen Faison. I’m a physician as well as a psychiatrist and I support predominantly the Women’s Health team but I also support the Neuroscience team as well. My hopes for the impact of this campaign is that the public will feel more comfortable about sharing what’s important to them in regards to their life their health their families and with that they’ll learn about key health issues and feel comfortable interacting with their health care professionals to make sure they have all the necessary information to make those important healthcare decisions.

Narrator
We live longer than we did a generation ago, and longer still than we did two generations ago. And that’s no surprise, really. Because if we at Pfizer keep doing our jobs right, there will be a side effect — you’ll Get Old. You’ll live longer and better. When you have more time, you get see more, do more, share more. You get to make more wrong turns, and explore new places. You get to experience more successes, and more failures. It’s a chance to live not just longer, but fuller. To hit your prime at 30, and 50, and every year after. To turn a time that was feared into a time to look forward to, and live long enough to find out what you’re here for. Ultimately, your job is to get to work on your dreams. At Pfizer, our job is to make sure you live long and well enough to achieve them. Tell us how you feel about getting old.